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CHAPTER I 
 
BACKGROUND 
 
HIV epidemic in China 
     Based upon a newly released report from the Chinese government, the number of 
people living with HIV/AIDS (PLWHA) in China was 501,000 by the end of 2014 
(UNAIDS & MoH, 2015). Although the national HIV epidemic categorizes China as a 
low-prevalence country, the trend of increasing pattern remains. For instance, the 
reported cases of PLWHA has increased from 272,000 in 2009, 307,000 in 2010, 352,000 
in 2011, 386,000 in 2012, 437,000 in 2013, to 401,000 in 2014 (NHFPC, 2014, 2015).  
The sharp increase of the epidemic among several high-risk groups indicates a serious 
and rapidly deteriorating situation (NHFPC, 2014).  
 
Role of MSM in the HIV epidemic in China 
     The most common transmission route for the HIV/AIDS epidemic in China has 
been shifting from injection drug use and contaminated plasma collection to unprotected 
sexual contacts in the last decade (Guo, Li, & Stanton, 2011; UNAIDS & MoH, 2015).  
The rapid increase in homosexual transmission is of a particular concern (Chow, Wilson, 
& Zhang, 2011a; Lu et al., 2013; J. R. Wu et al., 2013; Ye et al., 2012). Although the 
dominant route is still heterosexual transmission, homosexual transmission among MSM 
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shows a marked uptrend. Accordingly, the male homosexual proportion of new infections 
increased from 2.5% in 2006 to 25.8% in 2014 (NHFPC, 2014, 2015).  In addition, the 
homophobia is prevalent and stigma against MSM is significant. In addition to the 
unstructured surveillance system in China, makes the HIV epidemic among MSM very 
likely to be underestimated (Lou et al., 2014; Z. Wu et al., 2013; Y. Zhou et al., 2014). 
 
Risk factors among MSM 
     A series of biological, behavioral and structural risk factors are embedded in the life 
context of MSM (Guo et al., 2011; Vermund & Qian, 2008). At the individual level, 
condomless receptive anal sex has been considered the most significant risk factor for 
HIV infection (Jin et al., 2010). Circumcised men who primarily conduct insertive sex 
have lower risk compared with their uncircumcised peers (Jin et al., 2010). Furthermore, 
MSM reporting substance use (Xu et al., 2014), multiple sex partners (Cheng et al., 2014; 
Chow et al., 2013), and psychological distress (Jiang, Cai, Pan, & Ma, 2014) are more 
susceptible to HIV infection. It is probably because these risk behaviors are markers for 
impaired decision-making, high risk taking, poor coping and low self-efficacy. At the 
intrapersonal and community level, MSM who encountered partner violence (Sabido et 
al., 2015), lacked access to HIV testing (Vutthikraivit, Lertnimitr, Chalardsakul, Imjaijitt, 
& Piyaraj, 2014), reported less social support from families and friends, and being socio-
economically disempowered (Steward, Miege, & Choi, 2013), were more likely to 
contract with HIV.  
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     At the social level, prevalent homophobia and stigma forces many MSM to hide 
their true identity and presents barriers for their seeking appropriate and timely healthcare 
(C. Wei et al., 2013). MSM experience even more severe stigma and discrimination in 
contexts highly influenced by Confucianism, such as China.  
     In China, men are supposed to fulfill their filial piety (In Confucian 
philosophy, filial piety is a virtue of respect for one's parents, elders, and ancestors). 
Therefore, majority of MSM will hide their true identity by getting married and having 
offspring to carry their family names (Steward et al., 2013). Homosexual behaviors are 
not viewed as a personal choice, but as evidence of moral weakness(Steward et al., 2013) 
Approximately more than half MSM in China live a “double life” by marrying with a 
woman to hide their true sexual identity, especially for the older ones (Pando et al., 
2013a). The hidden identity may further exacerbate the epidemic by preventing MSM 
from seeking for health care and HIV prevention outreaches.  
 
HIV prevention interventions among Chinese MSM 
     Although the ever-increasing HIV epidemic explodes among Chinese MSM, no 
effective interventions are available (Guo et al., 2011). Condoms can effectively prevent 
HIV transmission, but only 20% MSM consistently use condoms during sexual activities 
(Guo et al., 2011; Zheng, 2009). Pre-exposure prophylaxis (PrEP) can be used by 
uninfected MSM, but uninfected individuals do not like to take antiretroviral drugs, and 
side effects discourage adherence. Therefore, VMMC might be a biomedical prevention 
that provides lifelong protection after a single procedure(Vermund & Qian, 2008).  
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Mechanisms of VMMC in preventing HIV transmission 
     Circumcision is likely to protect men from acquiring HIV by eliminating the most 
vulnerable mucosal surface areas and HIV target cells in a minimally keratinized zone, 
the inner surface of the penile prepuce(Donoval et al., 2006; Vermund & Qian, 2008). 
Both observational studies and large randomized controlled trials (RCT) have shown that 
voluntary medical male circumcision (VMMC) reduces the risk of HIV acquisition by 
over half in heterosexual men living in high prevalence areas of Africa(Auvert et al., 
2005; Bailey et al., 2007; R. H. Gray, Kigozi, et al., 2007). Although the evidence on the 
relationship between VMMC and HIV risk among MSM has been inconclusive, 
protective effects were observed among men who practiced insertive sex (Beyrer, 2010a; 
Doerner et al., 2013b; Fankem, Wiysonge, & Hankins, 2008; Gust et al., 2010; Jameson, 
Celum, Manhart, Menza, & Golden, 2010a; Jozkowski et al., 2010; Londish, Templeton, 
Regan, Kaldor, & Murray, 2010b; Sanchez et al., 2011; Schneider et al., 2012b; 
Wiysonge et al., 2011; C. Zhou et al., 2012). Therefore, circumcision may be considered 
a cost-effective biomedical tool, which is viable to add it to a critical layer of enhancing 
prevention intervention among MSM.  
     A series of observational studies and three randomized controlled trials (RCT) 
conducted in sub-Saharan Africa have proven the promising effectiveness of VMMC 
against HIV among heterosexual men (Auvert et al., 2005; Bailey et al., 2007; R. H. 
Gray, Kigozi, et al., 2007; Millett, Flores, Marks, Reed, & Herbst, 2008; Wiysonge et al., 
2011). A meta-analysis of  RCT data, suggested 56% reduction in the relative risk 
(RR=0.44, 95%CI=0.33-0.60) among circumcised men compared to their uncircumcised 
peers (Mills, Cooper, Anema, & Guyatt, 2008). Their conclusion gained support from 
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another meta-analysis of 27 studies based upon observational data (Weiss et al., 2008; 
Weiss, Quigley, & Hayes, 2000). After adjusting potential confounders, the authors found 
a strong association between VMMC and reduced relative risk (RR=0.42, 95% CI=0.34-
0.54).   
     The role of VMMC in preventing HIV infection among MSM is controversial 
(Millett et al., 2008; Qian et al., 2015; Vermund & Qian, 2008). For instance, two studies 
conducted in areas with dense HIV prevalence, VMMC was found to reduce HIV risk 
significantly among MSM (Schneider et al., 2012a). Even among males who primarily 
conducted receptive sex, circumcision exerted a significantly protective effect (Schneider 
et al., 2012a). However, as indicated in a meta-analysis, the effects of VMMC against 
HIV infection were not significant among this at-risk population (Wiysonge et al., 2011).  
Furthermore, the potentially protective evidence of VMMC in MSM studies with the less 
rigorous study design, favors further investigators of this strategy for HIV prevention 
among this population.  On the other hand, a most recent study conducted in 2015 among 
MSM in Beijing revealed the strongest protection effect among Chinese MSM who 
predominately practice insertive sex (aOR=0.15, 95%CI=0.04, 0.65). This study 
suggested that circumcision was significantly associated with lower odds of HIV 
infection among MSM practicing insertive anal sex, with a strong beneficial trend for 
other MSM as well, providing the strongest evidence to date that VMMC might be a 
useful biomedical tool for HIV risk reduction among MSM. 
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Feasibility of scaling up VMMC among MSM in China 
     Although VMMC has been considered as a medical practice that specifically 
applied to men with phimosis and redundant prepuce in China for a long time, with the 
increasingly scaling-up educational programs launched, many people have recognized its 
protective effects for HIV and other sexually transmitted diseases (STD). Based upon 
several studies conducted among Chinese males, the willingness of VMMC uptake 
ranged from less than one-third among male miners in Guangxi (F. M. Wei et al., 2012), 
to more than two-thirds among general male population who received an intervention for 
circumcision promotion (Luo et al., 2011; Ruan et al., 2009).  In studies conducted 
specifically among MSM, their willingness for receiving VMMC is consistent with the 
general population, among whom two-thirds of them expressed their willingness of 
accepting the VMMC as a strategy to prevent HIV and other STD (Lau et al., 2011; Luo 
et al., 2011). In addition, younger MSM tend to be less influenced by the Chinese 
traditional culture and are more likely to accept new ideas and challenge the status-quo 
(Liu H, 2001). For instance, compared with MSM who were 40 years or older, only 11% 
of younger MSM got married, which was only one-fifth of the older MSM (11% vs. 
64%) (Chow, Wilson, & Zhang, 2011b).  
     In addition, well-designed interventions can facilitate greater willingness of 
accepting VMMC among MSM in China (Lau et al., 2012). For instance, an intervention 
successfully increased the willingness of up-taking circumcision from 8.1% to 35.1% 
among a group of bisexual MSM in Southern China (Lau et al., 2012). Furthermore, 
newborn circumcision in western countries (e.g., United States) has made great 
contribution to curbing the HIV epidemic among at-risk population (Matar, Zhu, Chen, & 
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Gust, 2015; Young et al., 2012). Therefore, with appropriate strategies, the potential of 
promoting VMMC among of MSM in China is promising, especially among the younger 
generation.   
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CHAPTER II 
 
SPECIFIC AIMS AND SIGNIFICANCE 
 
Specific Aims 
     The primary objective of this research project is to evaluate the protective efficacy, 
epidemiological and economic impacts of voluntary medical male circumcision as an 
intervention strategy to reduce HIV infection among MSM population in China. 
Therefore, (1) we will conduct a systematic review and meta-analysis to evaluate the 
protective efficacy of the association between male circumcision and HIV infection 
among MSM with a series of sensitivity analyses; (2) we will employ a transmission 
model to assess the epidemiological impact of VMMC by projecting the HIV incidence 
for the next decade among MSM in Beijing; and (3) we will determine the budget-impact 
of VMMC program by a decision-modeling strategy.  
     Aim 1: To conduct a systematic review and meta-analysis to assess the 
association between VMMC and HIV infection among MSM. We will systematically 
review and conduct meta-analyses of outcomes in observational studies, and to 
summarize the magnitude of association between VMMC and HIV infection among 
MSM. In addition, stratified subgroup analyses will be employed to examine if the effect 
of VMMC differs by different characteristics of individuals and settings, including sex 
position (receptive vs. insertive), study design (cross-sectional vs. studies with follow-
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ups), geographical regions (Asia vs. non-Asia; Asia+African vs. non-Asia/non-Africa), 
assessment methods (self-reported vs. medical exam), and sample size at baseline 
(<=3000 vs. >3000).  
     Aim 2: To project HIV incidence for the next decade among MSM in Beijing 
using a transmission model. We will employ a deterministic compartmental modeling 
procedure to fit prevalence from 2005-2015. We will project new HIV cases during 2016-
2026 under different coverage rates ranging from 0.0001 (at baseline) to 0.15 (an 
optimistic assumption) with simulation on varying transmission rates, model calibration 
to match historical data, and sensitivity analyses for several assumptions. We hypothesize 
that projected HIV incidence among MSM in Beijing will be reduced by greater use of 
VMMC. 
     Aim 3: To assess the economic impact of scaled-up VMMC program in China.  
We will use a deterministic compartmental model to project new HIV cases (2016-2026) 
under circumcision coverage rates (λ) ranging from 0.0001 (very low coverage at 
baseline) to 0.15 (15% of MSM circumcised/year). We will conduct simulations using 
varying transmission rates. The ratio of the number of VMMC per new HIV case averted 
was the indicator used for the budget-impact analysis. The lower this ratio, the more 
economical VMMC would be for HIV prevention among MSM. 
     In summary, Aim 1 evaluates the protective efficacy of the VMMC and assesses 
whether VMMC is associated with lower HIV risks, and provides the efficacy data for 
the Aim 2 and Aim 3. Aim2 projects HIV incidence/prevalence for the next 10 years 
using a HIV transmission model, which can serve as the foundation for Aim 3. Aim 3 
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evaluates the economic impact of VMMC scale-up among MSM in China.  With the 
assistance of Aim 1-3, decision-makers can comprehensively assess the efficacy and 
effectiveness of VMMC among MSM.   
 
Significance of Aim 1 
     Two previous published meta-analyses have examined the efficacy of protection of 
VMMC among MSM in the past few years. The earlier meta-analysis of 15 studies from 
VMMC interventions demonstrated that there was insufficient evidence that male 
circumcision protected against HIV infection or other STIs among MSM (Millett et al., 
2008). In the later meta-analysis of 21 studies examined the effect of VMMC by sexual 
position (insertive vs. receptive) and found a strong protective effect among MSM who 
primarily practice insertive anal sex (odds ratio [OR], 0.27; 95% confidence interval [CI], 
0.17-0.44) (Wiysonge et al., 2011).  Since then, with the increasing emphasis on VMMC 
strategy among MSM, several more studies with rigorous design have been published 
(Pando et al., 2013b; Templeton, Millett, & Grulich, 2010; Thornton, Lattimore, Delpech, 
Weiss, & Elford, 2011; Zeng et al., 2014), including the study indicating the strongest 
protective effect of VMMC in Chinese MSM to date (Doerner et al., 2013a; Qian et al., 
2015).  In addition, neither of the meta-analysis have assessed the context specific 
characteristics (e.g., Asia vs. non-Asia; resource-rich vs. resource-limited settings; high-
prevalence vs. low-prevalence; receptive vs. insertive), which can provided more specific 
and tailored information for interventions in future. The efficacy and effectiveness of 
VMMC may differ by settings with different social, cultural, and contextual 
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characteristics.  To date, we have seven articles from Asia, twenty-four articles from non-
Asian countries; eight addressed in the resource-limited settings vs 23 in resource-rich 
settings; five conducted among high-prevalence countries vs. 26 among low-prevalence 
countries; five examined the effect of insertive-position, and nine assessed the effect of 
receptive position.  Therefore, we have sufficient resources to provide context-specific 
effect of circumcision among MSM.  Furthermore, with the efficacy of protection from 
the meta-analysis, we can use them as parameters in the following mathematical model 
and cost-effectiveness analysis.   
 
Significance of Aim 2 
     The Mathematical modeling approach has been used to estimate the impact of 
VMMC on reducing HIV risk among MSM in Beijing, China (Group, 2009).Several 
studies utilized parameters in published studies to project key factor pertaining to HIV 
epidemic including HIV incidence, prevalence, and number of male circumcision 
required for each  infection averted (R. H. Gray, Li, et al., 2007; Group, 2009; Hallett et 
al., 2008; Nagelkerke, Moses, de Vlas, & Bailey, 2007; White et al., 2008; Williams et 
al., 2006). However, most available studies were conducted in African settings among 
heterosexual populations. Very few studies examined the impact of VMMC among 
MSM.  One mathematical model simulated and projected HIV epidemic in the next ten 
years among MSM in Beijing under different scenarios of combination of intervention 
strategies including uptake of HIV testing, linkage, ART initiation, and condom use (Lou 
et al., 2014).  Another recently published study specifically examined whether male 
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circumcision had an impact on HIV epidemic in MSM in Peru (Goodreau et al., 2014). 
By stratifying three levels of insertive sex (e.g., 100%, >80% or >60%) during 
condomless anal sex and two levels of uptakes of circumcision among eligible men (e.g., 
25% or 50%), investigators concluded that introducing circumcision programs among 
MSM would not mitigate the HIV epidemic in Peru. However, authors made an 
assumption that overly underestimated the efficacy of VMMC among MSM without 
considering a most recent study with strongest efficacy to date (Qian et al., 2015).   
     Although these studies have either addressed the male circumcision or conducted 
among MSM, none of them specifically addressed the impact of VMMC among MSM in 
the setting of China, which has a significantly different social, cultural and epidemic 
environment, for example VMMC is not a traditional practice among Chinese men, and 
VMMC use is low. Establishing a HIV transmission model, we can evaluate the projected 
epidemiological impacts of VMMC among MSM in Beijing City, China  
 
Significance of Aim 3 
     To assess long-term population-level impacts of expanding VMMC among MSM, 
we should consider the balance between costs (e.g., numbers of VMMC performed) and 
impact (e.g., numbers of new HIV cases averted). The United States Agency for 
International Development (USAID) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) have developed a modeling tool called “Decision Makers’ 
Program Planning Tool” (DMPPT) to facilitate decision makers’ estimates of the 
epidemiological impact and cost of alternative programmatic options for scaling up 
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VMMC (Kripke & Njeuhmeli, 2016; Kripke et al., 2016; Njeuhmeli et al., 2011). 
However, these model-based studies only focused on heterosexual sexual men in specific 
settings with generalized HIV epidemics, e.g., African nations (Bollinger et al., 2009; 
Kripke & Njeuhmeli, 2016; Njeuhmeli et al., 2011; Stover et al., 2016). 
     The DMPPT model assumes the HIV incidence rate to remain constant during the 
prediction period, resulting in potentially over- or underestimating the impact of VMMC 
(Kripke et al., 2016). To date, no analogous modeling studies have specifically addressed 
the potential utility of circumcision programs targeting MSM; given the lower prevalence 
of VMMC in China and comparatively low to moderate risk profiles among MSM 
(Beyrer et al., 2012; Vermund & Qian, 2008; Zhang, Qian, Liu, & Vermund, Under 
review), it is conceivable that VMMC would have a greater impact than in areas of high 
circumcision prevalence (e.g., the United States) or in areas where at-risk MSM have 
higher risk behaviors. In order to assess context-specific impacts of VMMC among MSM 
in China, we conducted the current cost-minimization analysis assess the extent to which 
expanding VMMC programs might reduce HIV incidence among MSM, addressing costs 
and cost-effectiveness.     
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CHAPTER III 
 
DATA AND METHODOLOGY 
 
Aim 1 
Overview  
     Aim 1 is to conduct a systematic review and meta-analysis to assess the efficacy of 
circumcision in preventing HIV infection presented in existing literature.  
     The primary research question is formulated as ‘can VMMC effectively reduce 
acquisition of HIV among MSM?’ VMMC is a procedure to remove the foreskin that 
covers the head of the penis. As the inner part of the foreskin is highly susceptible to HIV 
infection, removal of the foreskin of infants, adolescents and adults by trained health 
professionals can help reduce the chance of HIV acquisition among males (Reynolds et 
al., 2004; Vermund & Qian, 2008). Acquisition of HIV is measured by either self-
reporting or blood testing.  My overall hypothesis is ‘MSM who receive the VMMC are 
less likely to have HIV acquisition compared to these who don’t receive the VMMC’. My 
secondary research question is whether the effect of VMMC on preventing HIV 
infection varied by individual (e.g., receptive verse insertive sex positions), contextual 
(e.g., Asia vs. Non-Asia; Asia+Africa vs. non-Asia and non-Africa), and study-design 
characteristics (e.g., sample sizes, sampling strategies). Details are discussed in the 
following subgroup analyses. 
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Eligibility criteria 
     Generally, studies that meet the following criteria will be included in the systematic 
review and meta-analysis: (1) Original studies published in English or in other languages 
(e.g., English, Spanish) between 1985 and 2016; (2) provided quantitative measurement 
of the effect of circumcision on HIV infection; (3) provided sufficient information to 
calculate effect size estimates; (4) conducted exclusively among MSM, or MSM 
subgroup from the total sample of the study; and (5) used a rigorous study design (e.g., 
randomized control trials, cross-sectional studies, longitudinal studies, observational 
studies). More specific criteria are presented in the following PICOS table. Exclusion 
criteria include (1) descriptive studies without quantitative outcomes; (2) studies with 
only qualitative outcomes; (3) studies that are not focused on MSM population; and (4) 
not original research.  
Literature search and study selection 
     A preliminary search will be conducted in PubMed to test and refine the search 
keyword as well as identify amount of relevant literature. Preliminary search keywords 
(Mesh terms) include: ("HIV"[Mesh] OR "HIV"[tiab] OR "HIV Infections"[Mesh] OR 
"HIV Antibodies"[Mesh] OR HIV-1[tiab] OR HIV1[tiab] OR HIV-2[tiab] OR 
HIV2[tiab] OR "HIV/AIDS"[tiab] OR "Sexually Transmitted Diseases, 
Viral"[Mesh:NoExp] OR "human immunodeficiency virus"[tiab] OR "human 
immunedeficiency virus"[tiab] OR "human immune deficiency virus"[tiab] OR 
"AIDS"[tiab] OR "acquired immunodeficiency syndrome"[tiab] OR "acquired 
immunedeficiency syndrome"[tiab] OR "acquired immune deficiency syndrome"[tiab]). 
The following table illustrates the searching procedure. In addition, an exploration of 
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‘related study’ will be performed to retrieve additional relevant articles that are missed by 
keyword-searching strategy. 
Comprehensive literature search 
     Twelve electronic databases will be searched. They are: AMED(Allied and 
Complementary Medicine Database, Ovid Technologies, Inc., New York), BIOSIS 
Previews (Biological Abstracts & Biological Abstracts/RRM, Thomson Scientific 
Technical Support, New York), British Nursing Index (Ovid Technologies, Inc., New 
York), EMBASE (Elsevier, Amsterdam, The Netherlands),  EconLit (The American 
Economic Association, New York),ERIC (Education Resources Information Centre, 
Institute of Education Sciences of the U.S. Department of Education, Washington), Ovid 
Medline (Ovid Technologies, Inc., New York), PsycINFO (American Psychological 
Association, Washington), Scopus(Elsevier, Amsterdam, The Netherlands), Web of 
Science (Thomson Scientific Technical Support, New York). In addition, I will also 
employ strategies like hand searches of key journal, harvesting reference, and forward 
citation searching to comprehensively search available articles.  
Grey literature search 
        Potential grey literatures will be searched through conference proceedings (e.g., 
APHA, IAS, AIDS-IMPACTS), governmental reports (e.g., WHO, UNAIDS), research 
reports, books and book chapters, libraries and archives, contacts with experts in the 
relevant field, explorations from organization websites, and ascertainment of relevant 
thesis via online resource. As supplements, I will also search databases like Cochrane 
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HIV/AIDS Group and Google Scholars. If anything unclear, I will contact with original 
authors for further information.  
Management of literatures    
     All titles and abstracts will be reviewed by two independent reviewers (CZ and YL) 
to determine whether the papers are relevant to the topic. Those considered irrelevant by 
both of the reviewer will be excluded. Then full texts of potentially relevant articles will 
be downloaded for further eligibility examination. Disagreement between reviewers will 
be resolved by discussion. Duplicates will be identified and removed. All included 
studies will be managed by Endnotes X7 (Thomson Reuters, 2014).  
Study selection and data extraction 
     Based upon inclusion and exclusion criteria (section 4.2.2), we will select all 
eligible studies for the following data extraction procedure.  
     Two reviewers will independently extract data from qualified articles using a 
standard screening form and developed a table containing the following information: 1) 
study location and time of conducting the study, 2) characteristics of participants (e.g., 
age, ethnicity), 3) sample size, 4) HIV infection (e.g., either self-report or lab work), 5) 
circumcision assessment (either self-report or genital examination), 6) sex positions if 
applicable (e.g., receptive vs. insertive), and 7) other information (e.g., inconsistent 
condom use, multiple partnership).  
    When information regarding any of the above information is unclear, we will contact 
the original authors of the included articles for further detailed information. For studies 
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with duplicate publications, we will report the study only once in the analyses.     
Assessment of risk of bias of included studies  
     Although Cochrane Handbook (Higgins JPT, 2011) has provided an empirical 
approach for assessing both internal and external validity of included studies, the 
approach is more appropriately for studies with randomized control trials (RCT). As 
majority of studies in the current review are observational studies which may have more 
inflated estimates than trials, I adopt an approach developed by RTI–UNC Evidence-
based Practice Center with the following criteria (ND et al., 2013) (Table 3).  
Statistical analysis plan  
Effect size calculation and aggregation 
     All calculated effect sizes (e., crude odds ratios and adjusted odds ratios) and 
standard errors (e.g., the square root of the variance) will be also be coded together with 
the above information in an EXCEL file, and will be converted to Stata file for further 
meta-analyses. 
     The major outcome of interests is the effect of VMMC on HIV infection. As all 
outcome variables were displayed as ORs with their 95% confidence intervals (95%CIs). 
For studies reporting raw data on HIV infection by their circumcision status, we 
calculated the OR and 95%CI directly. For studies without providing the raw data, we 
employed either reported crude or adjusted ORs with relevant 95%CIs from the text. For 
studies reported RRs, we can transfer RRs to ORs using the standard formula. For 
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prevalence less than 10%, RRs can be approximately equal to ORs (M. Borenstein, L. V. 
Hedges, J. P. T. Higgins, & H. R. Rothstein, 2009).  
Choice of analytical model 
     In the current analysis, I will choose the random-effects model as included studies 
will differ in terms of characteristics of participants (e.g., older vs. younger, more 
educated vs. less educated) and study settings (e.g., Asian vs. non-Asian). It is possible 
that the true effect size varies from study to study. Random-effects model captures a 
distribution of true effect sizes and estimates the mean of this distribution (Borenstein, 
Hedges, Higgins, & Rothstein, 2010; Borenstein & Higgins, 2013; Nikolakopoulou, 
Mavridis, & Salanti, 2014).   
     Alternatively, if we can find resource of raw data from each study, we can pool all 
participants and employ the formula to calculate a weighted average of the estimates of 
the RR or OR across the strata. The weighted average provides a measure of an 
association that is adjusted for confounding variables (e.g., by stratification)(LaMorte & 
Sullivan, 2016).   
Heterogeneity assessment 
     To quantify the heterogeneity of effect sizes over all included studies, three 
statistics will be calculated (‘metan’ command in STATA), including Tau-squared (τ2) 
statistics, I
2
 statistics and the Q statistics with P-value(Egger, Smith, & Altman, 2001; 
Higgins, Thompson, Deeks, & Altman, 2003).  
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     τ2 statistics is defined as the variance of the true effect sizes. It will give an estimate 
the between-study variance, representing the variability of effect sizes across the 
population of mean effect size values.  
     I
2 
statistics represent a ratio of true heterogeneity to total variance across the 
observed effect estimates.  It explains how much heterogeneity is due to true 
heterogeneity rather than sampling error. If I
2 
is near zero, almost all
 
observed variance is 
spurious (e.g., due to sampling errors); otherwise, the variance deserves explanations by 
subgroups analyses or meta-regression (Borenstein et al., 2010; Borenstein & Higgins, 
2013; Higgins & Thompson, 2002).   
     Q statistics has on a Chi-squared sampling distribution with (k-1)  degrees of 
freedom (k is the # of included studies), and it is used to test whether observed 
differences in effect sizes are consistent with what we would expected due to sample 
errors alone (The null hypothesis is: heterogeneity in ES is due to chance). A significant 
P-value provides that the true ES vary across studies; but a non-significant p-value could 
be due to low power, but not the evidence of consistent effect size across studies 
(Borenstein et al., 2010; Borenstein & Higgins, 2013; Brown, Upchurch, & Acton, 2003). 
     All these three statistics will be presented to assess the heterogeneity of the meta-
analysis. In addition, I will draw a Galbaith Plot (a scatter plot of inverse standard error 
[X-axis] against a standardized effect size [effect size divided by its standard error, Y-
axis]) to display heterogeneity (by “galbr” command in STATA). All points would lie 
within confidence bounds of unweighted regression if no heterogeneity exists.   
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Subgroup and moderator analysis  
     In addition to the overall assessment of the protective effect of circumcision on HIV 
infection, we will conduct the following subgroup analyses:  
     By sex positions: Previous studies suggested that MSM who had different anal sex 
positions or sexual roles have different levels of HIV risk (Wiysonge et al., 2011). In our 
review, we will perform stratified analysis by sex position (e.g., predominately receptive, 
predominately insertive, and predominately versatile). We anticipate that VMMC has a 
higher protective effect among MSM who predominantly practise insertive anal sex 
compared to those who prefer receptive or versatile anal sex.   
     By study design:  Among all 33 studies, 24 employed cross-sectional study designs. 
A protective and significant association was noted among the 24 studies with cross-
sectional design (aOR=0.92, 95% CI=0.87, 0.98). The nine studies with follow-up 
designs (Bartholow et al., 2006; Buchbinder et al., 2008; Buchbinder et al., 2005; Chen et 
al., 2011; Gust et al., 2010; Jameson, Celum, Manhart, Menza, & Golden, 2010b; Koblin 
et al., 2012; Sanchez et al., 2009; Templeton et al., 2009) revealed a non-significant 
association (aOR=1.01, 95% CI=0.86, 1.19) (Table 1).  
     By region: Compared to Western and African regions, HIV epidemic in Asia is 
featured by relatively delayed starting time of the epidemic, low-prevalence and 
concentrated epidemics. For instance, while other parts of the world began to deal with 
HI/AIDS epidemic, Asia remained unaffected (AVERT, 2015). However, by the early 
1990s, HIV epidemic had emerged in this continent with a rapid increase.  Although the 
prevalence is relatively low compared to countries in other regions, the huge population 
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in several countries (e.g., China, India) made the absolute number of PLWHA very 
significant. The epidemic among a few high-risk groups was spreading very fast, 
especially among MSM (AVERT, 2015). Therefore, in the current review, we will 
examine the circumcision effect within and outside Asia. We assume the effect may be 
different from Asia and the other part of the world.  Therefore, we will conduct subgroup 
analyses by study regions (a) Asia vs. non-Asia and (b) Asian and African vs. other 
regions  
     By sample size: We will further examine studies with different sample sizes. We 
will compare effect size between studies with no more than 3,000 participants and studies 
with sample sizes larger than 3,000. The effect size may be affected by sample sizes.  
     By sampling strategy: We assessed studies by the reported sampling strategy. For 
studies employed convenience sampling, we will compare the pooled effect size with 
studies employing some kind of systematic sampling. We will also examine studies with 
probability sampling and non-probability sampling.  
     By assessment method: We will compare studies employing medical exams for both 
exposure (e.g., circumcision status) and outcome variables (e.g., HIV serostatus) with 
studies employing self-reported measures for both variables. The rest of the 18 studies 
with either, but not both measures using a medical exam had a marginally significant 
HIV prevention benefit suggested for circumcision (0.93, 95% CI=0.88, 0.99) (Table 1).  
Publication bias assessment 
     The publication bias was assessed by the funnel plots (the standard error of the 
effect size will be plotted against the effect size). The funnel plot is based on the 
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assumption that in the absence of significant heterogeneity, study ESs will be normally 
distributed around the mean effects. Publication bias will produce asymmetry within the 
funnel, because studies with statistically significant effects in the desired direction will be 
available while those with null and contradictory results will be missing.  
     Then, regression tests will be performed for funnel plot asymmetry. Egger test will 
be used as it is the recommended test for mean or percent change effect sizes, and has 
more power and less inflated type I error than Begg’s test does. (Moreno et al., 2009; 
Sutton, Duval, Tweedie, Abrams, & Jones, 2000) P-value from the global regression test, 
or the coefficient of ‘bias’ will be used make decision whether or not to reject the null 
hypothesis of no small study effects or possible evidence of publication bias. The last 
step assessing the publication bias is to perform a ‘trimmed and filled’ procedure to yield 
an ‘unbiased’ estimated, and compares it to the original estimate to examine if they are 
significantly different (Duval & Tweedie, 2000; Sutton et al., 2000). 
Sensitivity analysis 
     Several sensitivity analyses will be conducted by removing studies with highest and 
lowest weight, and studies with largest and smallest sample size, respectively. In 
addition, I will compare the result from the sensitivity analyses with our original 
outcome. Meanwhile, I will assess the overall effects for studies with only crude ORs, 
and studies with adjusted ORs, respectively. By comparing the overall effects with 
unadjusted and adjusted ORs, we can evaluate if confounding is an issue to assess the 
intervention effect among this population.   
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Aim 2 
Model structure 
      We will employ a deterministic compartmental model to predict the impacts of 
VMMC on HIV acquisition over the next 10 years. As being circumcised may change the 
risk of HIV transmission significantly among MSM (Goodreau et al., 2014; Goodreau et 
al., 2012; Qian et al., 2015), the study population will be divided into two mutually 
exclusive subgroups: 1) MSM without circumcision (Sc-) and 2) MSM with circumcision 
(Sc+). These two subgroups each will be further compartmentalized by HIV infection 
(HIV positive with circumcision vs. HIV negative without circumcision). In this model, 
seronegative MSM will enter the model as the susceptible population with a rate of σ; σ+ 
will represent the rate entering the circumcised susceptible pool, while σ- will represent 
the rate entering the uncircumcised susceptible pool. Meanwhile, MSM will leave the 
local transmission model by aging beyond 65 years, emigrating out of Beijing, or dying 
of natural causes. We will use the parameter τ to indicate rates of leaving the model 
among susceptible MSM, with τ+ representing the rate of leaving the circumcised 
susceptible pool and τ- representing the rate of leaving the uncircumcised susceptible 
pool. In this model, MSM will change from being uncircumcised to being circumcised at 
a rate of λ at susceptible stage.  
     Uncircumcised MSM will become infected and enter the compartment of HIV-
infected with circumcision (Ic-) at an HIV transmission rate of ρ
-
;  and circumcised MSM 
will become infected (Ic+)  at a transmission rate of ρ
+
. Both circumcised and 
uncircumcised MSM will leave the infectious pool for the following reasons: 1) 
progression to AIDS, 2) death due to HIV infection, 3) having undetectable viral loads 
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due to either elite controller or an effective ART regime at a rate of 𝜂− for uncircumcised 
and  𝜂+ for circumcised MSM (see the schematic diagram below). This model will also 
consider the protective effect of VMMC on the basis of exclusively insertive, versatile, or 
exclusively receptive anal sex as they will affect the transmission rate of ρ+ and ρ-. 
Therefore, sexual position preference information is crucial for the model.  
Transmission rate of ρ- and ρ+ 
     ρ-: we will use the actual data of HIV cases from China CDC to calculate 
transmission rate among uncircumcised MSM. As the prevalence of circumcision is very 
low among MSM in China, we can use the calculated rate as the proxy of transmission 
rate among uncircumcised MSM in Beijing (Table 5).  
     ρ+ : we will estimate the transmission rate among circumcised MSM (ρ+)  using the 
transmission rate among uncircumcised (ρ-) and the pooled efficacy (OR) from Aim I.  
     The following table shows the actual incidence rate among uncircumcised MSM as 
well as the estimated transmission rate among circumcised MSM.  
     Relationship between odds ratio (OR), incidence, and prevalence: 
 OR=odds of HIV infection among circumcised/odds of HIV infection among 
uncircumcised=[prev1/(1-prev1)] /[prev2/(1-prev2)] 
 Prevalence = Incidence*Average Duration of HIV/AIDS  
 Prev1 is the HIV prevalence among circumcised MSM 
 Prev2 is the HIV prevalence among uncircumcised MSM (from China CDC data) 
 OR is calculated from Aim 1  
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 Duration: On average, life expectancy is 14.9 years with ART treatment after the 
incubation time (averagely 8 years), and 1.6 years without ART treatment for a given 
patient(April et al., 2014; Binagwaho, Pegurri, Muita, & Bertozzi, 2010; Walensky et al., 
2006).  With 50% ART coverage rate in China(NHFPC, 2015),  the average during of 
HIV/AIDS is approximately 16 years from HIV diagnosis to death considering both 
scenarios of ART and non-ART. 
ρ+ and ρ- (transmission rate per year) 
     To find out prediction interval for ρ- / ρ+ using R® software.  For each specific year, 
100 times simulations will be conducted to assess the variability in prediction due to 
randomness of the transformation rate (ρ- / ρ+). This model is more practical to use as it 
captures both the trend and randomness of this parameters.  
 Prediction model to calculate number of HIV cases averted  
     To building prediction model for the next decade, we will use the 2015 data as the 
new initial condition to project the HIV incidence from 2016-2025. We will use the pre-
scale up parameter to calculate the HIV incidence per year as the numbers of baseline 
cases. Based upon different VMMC coverage rates, I will compare the HIV cases at a 
given VMMC coverage rate with the baseline case in each year. The difference between 
the number of HIV cases of a given VMMC coverage rate and the number of HIV cases 
at the baseline will be the number of HIV cases averted per year.  I will calculate the 
number of HIV cases averted based upon the three scenarios including predominately 
receptive, predominately insertive and predominately versatile (Table 8).  
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Aim 3 
Rationale:   
     In this proposal, I will compare the scale up of VMMC vs. status-quo (e.g., remain 
at the pre-scale-up level) from the both societal and payer’s perspective. Examining from 
the societal perspective will considers everyone affected by the intervention and counts 
all significant health outcomes and costs that related with it, regardless of who experience 
the outcomes or costs (Gold, Siegel, Russel, & Weinstein, 1996). Examining from 
payer’s perspective, I can identify the most cost-saving strategy to curb the HIV 
epidemic. As economists view the maximization of the social utility function as the 
ultimate scheme for resource allocation, cost-minimization analysis will be used as a tool 
to better allocate social resources and improve general welfare.  
Economic evaluation:   
     In order to assess the economic impact for VMMC scale-up among MSM, I will 
conduct the current analysis from the perspectives of budget holders and health 
professionals (Sullivan et al., 2014). We employed the “numbers needed to avert” 
(NNA) that defined as “the number of VMMC per new HIV case averted” as an 
indicator. NNA was calculated by dividing the number of HIV cases averted (compared 
with the baseline [λ=0.0001]) by the number of VMMC conducted at a given year. The 
lower the NNA, the more economically effective the VMMC campaign would be among 
MSM. We calculated the NNA under different annual VMMC coverage rates at each 
predicted year.  
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     In addition, we further identified the breakeven point that balances the total cost of 
VMMC with the cost saved from averting new HIV cases. The breakeven point can be 
considered as the tipping point that it was economically desirable to proceed with the 
VMMC program among MSM in Beijing. We also calculated the total cost saved 
compared to the cost at baseline after expanding the VMMC program in each projected 
year. The cost at each scenario included the cost of VMMC and cost of HIV treatment. 
The cost of each individual VMMC and HIV treatment in each projected year (2016-
2026) was discounted by 3% (Hunink et al., 2001)that started from the baseline cost 
derived from existing studies (Drabo, Hay, Vardavas, Wagner, & Sood, 2016; Farnham et 
al., 2013; Moon et al., 2008; Schackman et al., 2015).  
Sensitivity analysis:  
     We conducted sensitivity analyses by setting the transmission rates for both 
circumcised and uncircumcised MSM at the same level as the incidence rate seen in 
2015. If nothing changes from 2015 (i.e., very, very few VMMC), it represents a lower 
bound for the transmission rate (Supplementary Figure 1). In addition, we assessed the 
economic impact in terms of the NNA and breakeven points by different protective 
efficacies(e.g., 7%, 17%, 27%, 37%, and 47%)  ranging from being very conservative 7% 
(Zhang, Qian, et al., Under review) to being optimistic 47%(Qian et al., 2016) 
incrementally in the current study.   
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CHAPTER IV 
EFFECT OF CIRCUMCISION ON RISK OF HIV INFECTION AMONG MEN WHO 
HAVE SEX WITH MEN:   A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Abstract 
Background: Despite the rapid increase of HIV among men who have sex with men 
(MSM) worldwide, the effectiveness of voluntary medical male circumcision (VMMC) 
as a tool for HIV prevention remains undetermined.  
Purpose: We conducted a systematic review and meta-analysis to assess the association 
between VMMC and HIV infection among MSM.  
Data sources: Following the PRISMA guidelines, we conducted a comprehensive 
literature search through multiple databases (PubMed/MEDLINE, Web of Science, 
PsycINFO, EMBASE, GOOGLE SCHOLAR) starting from February, 1 to August, 4 
2016.  
Study selection: From 117 suggestive titles, we identified 37 articles/abstracts from 33 
studies that had a rigorous enough study design to be included in the analysis.  
Data extraction: Two reviewers independently extracted data from qualified articles using 
a standard screening form. The risk of bias including selection, misclassification, and 
publication biases were assessed.  
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Data synthesis: We employed random-effects models and subgroup analyses based upon 
key study characteristics. A total of 117,293 MSM were included in the meta-analysis. 
The odds of being HIV positive were 7% lower among MSM who were circumcised than 
among MSM who were uncircumcised (aOR=0.93, 95% CI=0.88, 0.99). The evidence 
for the protective effect of VMMC was stronger among MSM who live in Asia and 
Africa (aOR= 0.62, 95% CI=0.53, 0.73).  
Limitations: The limited number and scope of existing studies constrained 
representativeness of our findings; misclassification of circumcision status and sex 
positioning may lead to a bias towards the null hypothesis; the nature of cross-sectional 
study designs may limit the inference of the association between VMMC and HIV.  
Conclusion: Our meta-analyses suggest a protective effect of VMMC against HIV 
infection among MSM, especially strong in Asian/African contexts.  
Key words: systematic review, meta-analysis, HIV, male circumcision, sexual 
positioning, Africa, Asia, men who have sex with men, homosexual men 
Introduction 
     Global HIV prevalence among men who have sex with men (MSM) ranges from 
3% in the Middle East and southeast north Africa to 25% in the Caribbean countries 
(Beyrer et al., 2012; van Griensven, de Lind van Wijngaarden, Baral, & Grulich, 2009). 
HIV incidence has increased in many global settings since declines were noted in the 
United States and western Europe in the mid-1980s, despite  available behavioral (e.g., 
risk reduction with condom use) and biomedical (e.g., pre-exposure prophylaxis [PrEP]) 
prevention tools (Vermund & Qian, 2008).  Given the urgency of the global HIV 
31 
 
epidemic in MSM, the available tools for preventing HIV acquisition among MSM may 
be too limited (Vermund & Qian, 2008).
  
Voluntary male medical circumcision (VMMC) 
is a single surgical procedure providing potential lifelong benefit (Vermund & Qian, 
2008). Both observational studies and clinical trials demonstrate that foreskin removal via 
VMMC reduces a man’s risk of contracting HIV through condomless heterosexual 
intercourses by 50-73% (Auvert et al., 2005; Bailey et al., 2007; R. Gray et al., 2012; R. 
H. Gray, Kigozi, et al., 2007).  The global public health community would be thrilled to 
have an “HIV vaccine” with efficacy at this level. 
     Many scholars have examined the efficacy of VMMC for preventing HIV 
transmission among MSM, but the conclusions have been inconsistent. Two research 
teams conducted systematic review and meta-analyses of available observational 
evidence and their findings were both inconclusive (Millett et al., 2007; Wiysonge et al., 
2011).  Millet et al. (2008) included 15 studies revealing insufficient evidence that 
VMMC protected against HIV infection among MSM (Millett et al., 2007). By including 
six more studies, Wiysonge et al. (2011) found the same overall conclusion, but data 
suggested that VMMC significantly protected MSM from HIV infection in the subgroup 
of men who primarily practiced insertive sex (Wiysonge et al., 2011).  
      Since the publishing of Wiysonge’s meta-analysis in 2011, twelve new 
epidemiological studies have been published (R. V. Barnabas et al., 2011; Chen et al., 
2011; Crosby et al., 2015; Doerner et al., 2013a; Jozkowski et al., 2010; Koblin et al., 
2013; Koblin et al., 2012; Oster et al., 2011; Pando et al., 2013a; Qian et al., 2016; 
Sanchez et al., 2011; Schneider et al., 2012a; Solomon et al., 2014; Thornton et al., 2011; 
Zeng et al., 2014; C. Zhou et al., 2013). For instance, a 2010-2011 study among MSM in 
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Beijing showed that circumcision was significantly associated with a lower odds of HIV 
infection among MSM predominantly practicing insertive anal sex, with a beneficial 
trend for other MSM as well, providing the strongest evidence to date that VMMC might 
be a useful biomedical tool for HIV risk reduction among MSM (Qian et al., 2016). Two 
other studies, both from India, similarly suggested strong protective effects of VMMC 
against HIV among MSM (Schneider et al., 2012a; Solomon et al., 2014).   
     Systematic reviews must incorporate social and contextual factors into their 
analyses, particularly the region of study and sexual position preferences. Compared to 
Western countries, the HIV epidemic in Asia differs in its later epidemic growth, 
comparatively low prevalence, and in the extreme social stigma faced by MSM (AVERT, 
2015). As MSM in Africa may share similar behavioral patterns and social stigmas as 
their Asian peers (Beyrer et al., 2012; Qian et al., 2016); region-specific strata can be 
compared to ensure that the comparatively vast literature on VMMC and MSM from the 
Americas and Europe does not drown out the comparatively small literature in Asia and 
Africa. Assessing the efficacy of VMMC among MSM by different characteristics of 
individuals and settings may also be revealing, e.g., sex positioning, study sample size, 
measurement for exposure and outcome variables, and type of study design. By exploring 
different subgroups, we sought to better understand the efficacy of VMMC on HIV under 
different circumstances.  
      Following PRISMA guidelines (http://www.prisma-statement.org/), we sought to 
compare the odds of HIV infection between circumcised and uncircumcised MSM by 
including all available studies with rigorous study design (e.g., randomized controlled 
trials, well-designed quasi-experimental designs, and observational study designs). In 
33 
 
addition, stratified subgroup analyses helped examine how the effect of VMMC might 
differ by different characteristics of individuals and settings.  
Methods 
Protocol and registration 
     We sought to register our meta-analysis with the PROSPERO, Cochrane, and 
Campbell systematic review databases, but were declined by all three for different 
reasons. Nonetheless, we followed PRISMA guidelines. 
Eligibility criteria 
     Inclusion: Studies were identified if they: (a) used a rigorous study design (e.g., 
randomized control trials, cross-sectional studies, longitudinal studies, observational 
studies with clear counterfactual constructs); (b) were quantitatively evaluating effects of 
circumcision on HIV risk among MSM; (c) provided sufficient information to calculate 
effect size estimates; (d) published (any language or year) either in peer-reviewed 
journals or in recognized conferences.  
     Exclusion criteria:  The exclusion criteria are (a) descriptive studies that do not 
report outcomes or studies only report qualitative outcomes, (b) studies that do not focus 
on MSM (e.g., focus on heterosexual men), (c) reviews, and (d) theoretical articles 
without original data.  
Data sources, Search Strategy and Study Selection  
     Following the PRISMA guidelines, we conducted comprehensive literature search 
through multiple databases including PubMed/MEDLINE, Web of Science, PsycINFO, 
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EMBASE, GOOGLE SCHOLAR by entering different combinations of a few MeSH 
terms (“HIV” OR “human immunodeficiency virus” OR “AIDS” OR “acquired 
immunodeficiency syndromes”) AND (“circumcision” OR “foreskin surgery”) AND 
(“men who have sex with men” OR ”MSM” OR “homosexual male” OR “gay men”) up 
to August 4, 2016 (Supplementary Table 1).  We also searched through newspapers and 
conference proceedings, as well as references from article that met our inclusion criteria. 
The initial screening yielded 92 potentially relevant articles/abstracts from 117 entries 
identified in the search or through other sources (Figure 1). These 92 abstracts were 
reviewed, 53 abstracts were excluded and 39 were retained for further review. Two 
reviewers (CZ and YL) independently reviewed the full texts of these articles. 
Disagreement between reviewers was resolved by discussion, and 33 articles fulfilled the 
inclusion criteria and were included in the analysis. We also hand-searched all references 
from included studies and relevant reviews. Four abstracts were selected based upon this 
review of references and all four were deemed eligible and their corresponding papers 
were included in the analysis (Calzavara, Remis, Myers, & StudyTeam, 2007; Kumta, 
Setia, Jerjani, Mather, & RaoKavi, 2002; Lai, Hong, & Lan, 2004; Solomon et al., 2014). 
Hence, 37 articles from 33 studies were included for the systematic review and meta-
analysis. 
Data Extraction 
     Two reviewers (CZ and YL) independently extracted data from qualified articles 
using a standard form and developed a table containing the following information: (a) 
study location and time of conducting the study, (b) characteristics of participants (e.g., 
age, ethnicity), (c) sample size, (d) HIV assessment (e.g., either self-report or lab work), 
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(e) circumcision assessment (either self-report or genital examination), (f) sex positions if 
applicable (e.g., receptive vs. insertive), (g) numbers of HIV infection among 
circumcised and uncircumcised MSM, and (h) reported crude and/or adjusted odds ratios 
of the HIV infection and VMMC. When information regarding any of the above 
information was unclear, we contacted the original authors of the included articles for 
further detailed information (Oster et al., 2011), but no further information has been 
provided. For studies with duplicate publications (R. V. Barnabas et al., 2011; 
Buchbinder et al., 2008; Koblin et al., 2012; Mao et al., 2008; Sanchez, 2007; Sanchez et 
al., 2009; Templeton et al., 2009), we reported the study only once in the analyses, with 
the most complete data included.  
Quality Assessment 
     Two reviewers (CZ and YL) independently assessed the risk of bias for each study. 
For our systematic review and meta-analysis, the selection bias may be unavoidable since 
we only considered articles with full-texts among widely accessible online resources. 
Publication bias occurred because published studies may not be representative of all 
studies that have ever been done. In addition, we assessed the rigor of measuring the 
exposure (self-report vs. genital examination) and outcome variables (self-report vs. 
laboratory testing) in the original studies. We also determined the quality of the sampling 
strategy for each study.   
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Statistical Analysis 
Measures of effects  
     Most studies reported strengths of association as odds ratio (OR) with 95% 
confidence interval (CI). We preferred using adjusted ORs with 95% CIs from the given 
publication, available for 28 studies (R. V. Barnabas et al., 2011; Bartholow et al., 2006; 
Begley et al., 2008; Buchbinder et al., 2008; Calzavara et al., 2007; Doerner et al., 2013a; 
Gust et al., 2010; Jameson et al., 2010b; Jozkowski et al., 2010; Koblin et al., 2013; 
Koblin et al., 2012; Kreiss & Hopkins, 1993; Kumta et al., 2002; Lai et al., 2004; Lane et 
al., 2011; Mao et al., 2008; McDaid, Weiss, & Hart, 2010; Mor, Kent, Kohn, & Klausner, 
2007; Oster et al., 2011; Qian et al., 2016; Reid, Weatherburn, Hickson, & Stephens, 
2001; Reisen, Zea, Poppen, & Bianchi, 2007; Sanchez, 2007; Sanchez et al., 2009; 
Sanchez et al., 2011; Schneider et al., 2012a; Tabet et al., 2002; Templeton et al., 2009; 
Templeton et al., 2008; Thornton et al., 2011; C. Zhou et al., 2013).  For five studies that 
did not report adjusted ORs, we used raw data to calculate the crude ORs and their 95% 
CIs (Chen et al., 2011; Crosby et al., 2015; Pando et al., 2013a; Solomon et al., 2014; 
Zeng et al., 2014).   
Assessment of heterogeneity  
     To evaluate the extent to which studies’ outcomes were consistent, we employed the 
I
2
-statistics and corresponding 95% CIs to depict heterogeneity. The I
2
-statistics 
describes the percentage of the variability in effect estimates that is due to heterogeneity 
rather than sampling error, and it varies from zero to 100% with higher percentages 
indicating higher heterogeneity (M. Borenstein, L. V. Hedges, J. Higgins, & H. 
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Rothstein, 2009). If the 95% CIs included zero, the included studies were considered to 
be reasonably homogeneous. P-values for I
2
-statistics were also reported.  
Assessment of publication bias  
     Publication bias was assessed by the funnel plots, based on the assumption that in 
the absence of significant heterogeneity, study effect sizes will be normally distributed 
around the mean effects (Michael Borenstein et al., 2009). Publication bias will produce 
asymmetry within the funnel, because studies with statistically significant effects in the 
desired direction will be published while those with null and contradictory results will be 
unavailable.  
Data synthesis  
     Model selection: We employed the random-effects model, as all included studies 
were conducted among different populations, a feature that may influence the effects 
observed. Unlike the fixed effects model that assumed that all studies shared identical 
true effect sizes, the random effects model was designed to capture the variance of effects 
across studies (Michael Borenstein et al., 2009; Littell, Corcoran, & Pillai, 2008). Each 
study was assigned a weight directly by the calculating procedure. Forest plot of odds 
ratios from included studies (shaded squares, is the proportional to weights used in meta-
analysis), with the summary measure (center line of diamond) and associated confidence 
intervals (lateral tips of diamond), and a solid vertical line of no effect was used. STATA 
V12 (College Station, TX); the command metan was used for data syntheses and 
analyses. 
     Subgroup analyses were performed to examine the effect size by sex positioning 
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(receptive vs. insertive), study design (cross-sectional vs. studies with follow-ups), 
geographical region (Asia vs. non-Asia; Asia+Africa vs. non-Asia/non-Africa), 
assessment method (self-report vs. genital exam), and sample size at baseline (≤3000 vs. 
>3000).  
     Sensitivity analyses were employed to examine the stability of the efficacy of 
circumcision by evaluating whether the overall effect size was sensitive to exclusion of 
any individual studies (e.g., study with highest or lowest weight, and with smallest or 
largest sample size).  
Role of the Funding Source 
      The study was supported by grants from U.S. National Institutes of Health 
(R01AI094562 and R34AI091446). The content is solely the responsibility of the authors 
and does not necessarily represent the sponsor who had no role in the design or conduct 
of the study, the writing of this report, or its submission for publication. 
Results 
Overall effect size  
     A total of 117,293 MSM participants from 33 studies contributed to examining the 
association between circumcision and HIV risk. Among these studies, four studies 
revealed that circumcision significantly reduced the odds of HIV infection among MSM 
(Chen et al., 2011; Lane et al., 2011; Schneider et al., 2012a; Solomon et al., 2014), while 
29 studies reported that circumcision had no statistically significant associations with 
HIV. The overall effect size of circumcision on HIV infection was statistically significant 
39 
 
(aOR, 0.93; 95% CI, 0.88-0.99) (Figure 2). In addition, details about each included study 
were presented in the supplementary Table 2. 
Subgroup analyses  
     By sex positioning: Among included studies, 11 studies (Calzavara et al., 2007; 
Doerner et al., 2013a; Jameson et al., 2010b; McDaid et al., 2010; Qian et al., 2016; 
Reisen et al., 2007; Sanchez, 2007; Sanchez et al., 2009; Sanchez et al., 2011; Templeton 
et al., 2009; Zeng et al., 2014) have reported circumcision data for insertive anal sex, and 
six studies (Jameson et al., 2010b; Pando et al., 2013a; Qian et al., 2016; Reisen et al., 
2007; Sanchez, 2007; Sanchez et al., 2009; Zeng et al., 2014) reported data on receptive 
anal sex among MSM. We performed stratified analysis by sex positioning (e.g., 
predominately or exclusively receptive vs. predominately or exclusively insertive anal 
sex). The results revealed that the odds of HIV risk among circumcised MSM who 
primarily/exclusively practiced insertive sex did not suggest protection (aOR, 1.16; 95% 
CI, 0.73-1.83), nor did the odds among circumcised MSM practicing receptive anal sex 
(aOR, 0.97; 95% CI, 0.74-1.28). However, the insertive sex group estimate was distorted 
substantially by a single study whose findings were highly disparate from other 
comparable studies (Zeng et al., 2014). When this one outlier study that suggested greater 
risk for circumcised men who primarily/exclusively practiced insertive sex was excluded, 
then the odds of HIV infection among circumcised MSM who primarily/exclusively 
practiced insertive sex (aOR, 0.51; 95% CI, 0.23-1.11) suggested a protective effective 
for circumcision among the insertive MSM (Table 1).   While not achieving statistical 
significance, the protective directionality and magnitude of the point estimate of the odds 
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ratio for MSM primarily practicing insertive anal intercourse is both notable and 
biologically plausible. 
     By study design:  Among all 33 studies, 24 employed a cross-sectional study design. 
A protective and significant association was noted among these studies (aOR, 0.92; 95% 
CI, 0.87-0.98). Nine studies with a cohort design (Bartholow et al., 2006; Buchbinder et 
al., 2008; Buchbinder et al., 2005; Chen et al., 2011; Gust et al., 2010; Jameson et al., 
2010b; Koblin et al., 2012; Sanchez et al., 2009; Templeton et al., 2009) revealed a non-
significant association (aOR, 1.01; 95% CI, 0.86-1.19) (Table 1).  
     By region:  (a) Asia vs. non-Asia: Eight studies (Chen et al., 2011; Kumta et al., 
2002; Lai et al., 2004; Qian et al., 2016; Schneider et al., 2012a; Solomon et al., 2014; 
Zeng et al., 2014; C. Zhou et al., 2013) were conducted in Asian countries, including five 
in China and three in India; the odds of being HIV infected were significantly lower 
among circumcised MSM compared to uncircumcised (aOR, 0.69; 95% CI, 0.58-0.81). 
Among non-Asian MSM, there was no protection of circumcision against HIV infection 
(aOR, 0.97; 95% CI, 0.91-1.03).  (b) Only one African study was found. Examining 
Asian/African studies combined meant adding the African study to the five Chinese and 
three Indian, revealing an even lower odds of being HIV infected among circumcised 
MSM (aOR, 0.62; 95% CI; 0.53-0.73) compared to Asian MSM alone. Similarly, the 
odds of HIV infection among circumcised MSM outside the Asian-African continents 
was still non-significant (aOR, 0.99; 95% CI, 0.93-1.05) (Table 1).  
     By sample size: For studies with ≤3,000 participants (n=24), we found the odds of 
being HIV infected among circumcised MSM was significantly lower (aOR, 0.70; 95% 
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CI, 0.61-0.82). For studies with a sample size >3,000 (n=9) (Bartholow et al., 2006; 
Buchbinder et al., 2005; Gust et al., 2010; Jameson et al., 2010b; Jozkowski et al., 2010; 
Mor et al., 2007; Oster et al., 2011; Reid et al., 2001; Solomon et al., 2014), the odd ratio 
of HIV infection was close to 1 (aOR, 0.99; 95% CI, 0.93-1.05) (Table 1).   
     By sampling strategy: Of 17 studies using a convenience sampling strategy, the 
odds of being HIV infected among circumcised MSM was 5% less compared with 
uncircumcised MSM (aOR, 0.95; 95% CI; 0.88-1.03). For studies employing some kind 
of systematic sampling, the odds of being HIV infected was significantly lower among 
circumcised MSM (aOR, 0.92; 95% CI, 0.85-0.99). Only five studies employed 
probability sampling (R. V. Barnabas et al., 2011; Bartholow et al., 2006; Buchbinder et 
al., 2008; Gust et al., 2010; Koblin et al., 2012; Sanchez et al., 2011), and the odds of 
being HIV infected was slightly lower among circumcised (aOR, 0.93; 95% CI, 0.88-
0.99), similar to the studies that did not use probability sampling (aOR, 0.95; 95% CI; 
0.68-1.34) (Table 1).  
     By assessment method: For nine studies employing genital exams to measure 
circumcision status and laboratory testing of HIV infection (Jameson et al., 2010b; 
Koblin et al., 2012; Kumta et al., 2002; Mor et al., 2007; Qian et al., 2016; Sanchez, 
2007; Sanchez et al., 2009; Sanchez et al., 2011; Tabet et al., 2002; Zeng et al., 2014), the 
odds of being HIV infected was similar between circumcised and uncircumcised MSM 
(aOR, 0.98; 95% CI, 0.90-1.07). For six studies employing self-report for both variables 
(Begley et al., 2008; Calzavara et al., 2007; Doerner et al., 2013a; Reid et al., 2001; 
Reisen et al., 2007; Thornton et al., 2011), the odds of getting HIV was also only slightly 
lower among circumcised men (aOR, 0.95; 95% CI, 0.75-1.20). The rest of the 18 studies 
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with either, but not both measures using a medical exam had a marginally significant 
HIV prevention benefit suggested for circumcision (aOR, 0.93; 95% CI, 0.88-0.99) 
(Table 1).  
Sensitivity analyses 
Sensitivity analyses were conducted by removing studies with highest and lowest 
weight, and studies with largest and smallest sample size, respectively. By comparing 
outcomes from sensitivity analyses with the original outcome, no difference has been 
found from the sensitivity analyses (not shown). In the subgroup analysis for men with an 
insertive sexual preference, a wide swing in adjusted odds ratio was noted when one 
study was excluded (Zeng et al., 2014). 
Publication bias assessment 
     The publication bias was assessed by the funnel plots in which the standard error of 
the effect size was plotted against the effect size. By examining the funnel plot, 
publication bias was present as the graph showed slight asymmetry within the funnel, 
especially among studies with smaller odds ratios (Figure 3). We further examined the 
heterogeneity using I
2
-statistics. The I
2
-statistic was 54.0% (P <0.001), indicating 
moderate heterogeneity of included studies (Michael Borenstein et al., 2009).  
Discussion 
     Our meta-analytic review included 117,293 participants from 33 studies, which had 
45,600 more participants and 12 new studies compared with the one conducted by 
Wiysonge  and colleagues in 2011 (Wiysonge et al., 2011). Our review showed that the 
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odds of being HIV-infected were significantly lower among MSM who were circumcised 
than among MSM who were uncircumcised, but the effect size was modest (7% 
protection, 95% CI, 1%-12%). Our meta-analysis is the first to report a statistically 
protective effect of VMMC against HIV infection among MSM. The evidence for the 
protective effect of VMMC was dramatically stronger among MSM who live in Asia or 
Africa. Our findings suggest that VMMC may be a protective tool against HIV infection 
among MSM, especially for these who living in Asia and Africa (Beyrer, 2010b; WHO, 
2016).    
     In addition to the overall effect size, several key findings emerged from the 
subgroup analyses. First, the observation that VMMC may be an especially effective tool 
for HIV prevention among Asian and African MSM generates a hypothesis that 
circumcision may be more effective in MSM who have comparatively lower risk profiles 
(e.g., fewer sexual partners, less risky sexual activity) comparing with their Western 
peers (Chen et al., 2011; Qian et al., 2016; Vermund & Qian, 2008). Therefore, we 
speculate that VMMC could be more effective among MSM with moderate risk, but that 
MSM with higher risk profiles may benefit less. Second, although our findings showed 
increased odds of HIV infection among MSM who primarily practicing insertive sex, a 
counterintuitive and biologically implausible finding was noted. A strong protective 
effect of VMMC on HIV infection among MSM exclusively or predominantly practicing 
insertive anal intercourse was noted after we removed an outlier from the analytic pool. 
There are, however, only a limited number of available studies that reported sex 
positioning. Third, for studies with a sample size ≤ 3,000 MSM, the odds of being HIV 
infection was 30% significantly lower among circumcised MSM compared to their 
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uncircumcised peers. On the other hand, the association was non-significant among 
studies with a larger sample size. Perhaps studies with fewer participants can be 
published only if they reported significant findings, while studies with larger sample sizes 
are published without bias, i.e., whether the association is significant or not. Therefore, 
we speculate that publication bias may affect the accuracy and reliability of the efficacy 
of VMMC, a bias away from the null hypothesis.   
     Our meta-analysis has several strengths. First, it included a large number of 
participants. Second, we stratified the data by individual and setting characteristics to 
capture any potential associations in important subgroups. Third, we strictly followed the 
PRISMA guidelines for systematic reviews and meta-analyses.  
     However, a number of limitations should be considered while interpreting findings 
from the current study. First, the limited number and scope of existing studies constrained 
representativeness of our findings. Of 33 studies, 22 (67%) were conducted in the U.S., 
Canada, Europe, or Australia, high income regions with long-standing 
lesbian/gay/bisexual/transgender (LGBT) civil rights movements and high HIV 
prevalence among MSM. This geographic concentration may not reflect the full scope of 
sexual risk and HIV transmission dynamics worldwide (Beyrer, 2010b; WHO, 2016). For 
instance, risk profiles of MSM are far less well characterized than in other continents, and 
only one MSM/circumcision study was reported, a study of just 363 Black MSM in South 
Africa(Lane et al., 2011). Even in Latin America (three studies, some mixed with other 
areas) or Asia (eight MSM/circumcision studies), the data are limited. It is possible that 
the 22 studies from the US (n=15) (R. V. Barnabas et al., 2011; Bartholow et al., 2006; 
Begley et al., 2008; Buchbinder et al., 2008; Buchbinder et al., 2005; Crosby et al., 2015; 
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Gust et al., 2010; Jameson et al., 2010b; Jozkowski et al., 2010; Koblin et al., 2013; 
Koblin et al., 2012; Kreiss & Hopkins, 1993; Millett et al., 2007; Mor et al., 2007; Oster 
et al., 2011; Reisen et al., 2007; Sanchez et al., 2011),  United Kingdom (n=4) (Doerner 
et al., 2013a; McDaid et al., 2010; Reid et al., 2001; Thornton et al., 2011), Australia 
(n=2) (R. V. Barnabas et al., 2011; Buchbinder et al., 2008; Koblin et al., 2012; Mao et 
al., 2008; Templeton et al., 2009), and Canada (n=1) (Calzavara et al., 2007) are 
underestimating the potential benefits of circumcision in other parts of the world, given 
their weak strength of association compared to the studies from Africa and Asia. The 
limited number of studies (n=13) from Asia (n=8) (Chen et al., 2011; Kumta et al., 2002; 
Lai et al., 2004; Qian et al., 2016; Solomon et al., 2014; Zeng et al., 2014; Zhao et al., 
2016; C. Zhou et al., 2013), Africa (n=1) (Lane et al., 2011) and Latin America (n=4) 
(Buchbinder et al., 2008; Buchbinder et al., 2005; Koblin et al., 2012; Pando et al., 
2013a; Sanchez, 2007; Sanchez et al., 2009; Tabet et al., 2002) limit our ability to 
generalize findings. 
     Second, misclassification of circumcision status and sex positioning may lead to a 
bias towards the null hypothesis, minimizing the ability to detect the true magnitude of 
association. Among all 33 included studies, only 10 studies (Jameson et al., 2010b; 
Koblin et al., 2012; Kumta et al., 2002; Mor et al., 2007; Qian et al., 2016; Sanchez, 
2007; Sanchez et al., 2009; Schneider et al., 2012a; Tabet et al., 2002; Zeng et al., 2014) 
conducted genital exam of MSM’s circumcision status, while the rest studies employed 
self-reported results. Although Templeton and colleagues have showed self-reported 
circumcision status was a valid measure among Anglo MSM in Australia and asserted 
that this can be generalized to MSM in developed countries (Templeton et al., 2008), a 
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Chinese study revealed the self-reported circumcision rate was higher than the rate from 
medical exams (Qian et al., 2016). Furthermore, for the 10 studies collecting sex 
positioning information (Calzavara et al., 2007; Doerner et al., 2013a; Jameson et al., 
2010b; Lane et al., 2011; McDaid et al., 2010; Pando et al., 2013a; Qian et al., 2016; 
Reisen et al., 2007; Sanchez, 2007; Templeton et al., 2009; Zeng et al., 2014), this 
measure was relied on self-reporting and was usually measured with a single question. 
The limited assessment of circumcision status and sex positioning may lead to 
misclassification that would tend to underestimate VMMC benefits (Qian et al., 2016; 
Wiysonge et al., 2011).  When reporting bias is eliminated by direct penile exam to assess 
circumcision status and by including detailed sexual position data, there may be more 
promise in VMMC as a tool to reduce HIV risk among MSM than previously assumed 
(Qian et al., 2016).  
     Third, data may be insufficient to answer the proposed question when the 
conclusion was derived incidentally, i.e., not through hypothesis testing. Many included 
studies examining the association between VMMC and HIV among MSM were 
generated from secondary analyses of existing data, rather than being designed 
specifically to address this issue (Doerner et al., 2013a; Zeng et al., 2014). This may 
result in residual confounding due to insufficient or incomplete measurements and/or 
may not address the specific research question with needed data (Boslaugh, 2007). For 
instance, several key studies were parts of HIV vaccine studies (R. V. Barnabas et al., 
2011; Buchbinder et al., 2008; Koblin et al., 2012) whose primary goal was examining 
vaccine efficacy, not the association between VMMC and HIV. In secondary analyses, 
reported associations may be biased due to uncontrolled confounding variables.  
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     Fourth, the nature of cross-sectional study designs may limit the inference of the 
association between VMMC and HIV. In our meta-analyses, two-thirds of included 
studies employed cross-sectional designs with convenience sampling, constraining casual 
inferences. Although a randomized controlled trial (RCT) could definitively determine 
whether VMMC reduces HIV risk among MSM, no available RCT has been conducted. 
Although a registered clinic trial (NCT01068015) started in 2009, we found no relevant 
publications regarding the effectiveness of VMMC among MSM from this trial 
(https://clinicaltrials.gov/ct2/show/record/NCT01068015).  In addition, our subgroup 
analysis among all cross-sectional studies revealed a protective association between 
VMMC and HIV risk, while the pooled OR among cohort studies was null. Perhaps the 
significantly protective association was driven by uncontrolled/unadjusted confounding 
in these cross-sectional studies. Studies with more rigorous design are highly desired.      
     Fifth, no analyses for the association between HIV-1 subtypes and circumcision 
have been reported. Molecular epidemiology exploits the classification of HIV-1 viruses 
into distinct phylogenetic strains (subtypes, inter-subtypes) and several recombinants 
(Beloukas et al., 2016; Konou et al., 2016; Zhao et al., 2016). These subtypes were 
significantly different from MSM with various regions; they may change over time even 
within a region (Konou et al., 2016; Zhao et al., 2016). Even for MSM with the same 
ethnicity, the subtypes can differ based on where, and from whom, the infection was 
acquired (Beloukas et al., 2016; Zhao et al., 2016). However, the mechanism on how 
each subtype might interact with circumcision intervention remains to be determined. 
Future research can study subtypes of HIV-1 can provide a framework to help us to 
understand how circumcision benefits, if any, might vary by subtype, along with the 
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aforementioned factors of the magnitude of sexual risk taking and sex positioning 
preferences.   
     Although the overall effect of VMMC on HIV prevention was marginally 
significant, misclassification of key exposure and confounding variables may dilute the 
protective effect of VMMC. In turn, publication bias may exaggerate its protective effort. 
Research with more rigorous study designs to objectively assess HIV infection through 
confirmatory serological tests and evaluation of circumcision by genital exam can 
significantly reduce misclassification bias. In addition, future research should collect 
detailed data on MSM’s sexual position preference at different time points in their lives 
(e.g., in the past 30 days, in the past six months and lifetime), as well as the degree of 
their sexual risk taking. We would not be surprised if we eventually learn that 
circumcision is highly protective for MSM, but benefits are predominantly accrued 
among men practicing predominantly insertive anal sex and men without highest risk 
behavior patterns. Subtypes may also alter the relative benefits seen, but no data exist on 
this point. A randomized clinical trial, if feasible, should be conducted. 
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Figure 1. Flow chart for study selection  
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as outcome (2), review 
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18 identified through other 
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discrete studies were 
included  
99 identified through 
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4 articles from the 
references of 
included studies 
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Figure 2. Overall effect size for 33 included studies of voluntary medical male circumcision 
and HIV risk (N=33)  
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Figure 3. Funnel Plot for publication bias assessment  
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Table 1. Subgroup analyses of included studies  
 # of studies # of participants aOR (95% CI) I
2
 p-value for heterogeneity 
chi-square 
Overall  33 117,293 0.93 (0.88, 0.99) 54% <0.0001 
By sex positioning       
Insertive  11 15,946 1.16 (0.73, 1.83) 14.6% 0.31 
Insertive (after delete Zeng et al., 
2014)
a
 
10 15,376 0.51 (0.23, 1.11) 0.00% 0.89 
Receptive  6 9,244 0.97 (0.74, 1.28) 28.0% 0.23 
By study regions      
Asia  8 17,458 0.69 (0.58, 0.81) 39.3% 0.12 
non-Asia 25 99,835 0.97 (0.91, 1.03) 45.0% 0.007 
Asia+Africa  9 17,821 0.62 (0.53, 0.73) 70.1% 0.001 
non Asia/non-Africa 24 99,472 0.99 (0.93, 1.05) 0.00% 0.86 
By sample size       
Smaller size (<3000) 24 22,510 0.70 (0.61, 0.82) 39.3% 0.024 
Larger size (≥3000) 9 94,783 0.98 (0.92, 1.04) 52.3% 0.033 
By study design      
Cross-sectional 24 92,937 0.92 (0.87, 0.98) 61.9% <0.0001 
Cohort  9 24,356 1.01 (0.86, 1.19) 0.0% 0.47 
By sampling strategy      
Convenience sampling  17 54,235 0.95 (0.88, 1.03) 41.6% 0.037 
Non-convenience sampling  16 63,058 0.92 (0.85, 0.99) 63.6% 0.000 
Non-probability-based   28 100,448 0.95 (0.68, 1.34) 0.0% 0.67 
Probability-based 5 16,845 0.93 (0.88, 0.99) 59.6 <0.0001 
By HIV testing       
Lab test  27 99,896 0.93 (0.88, 0.99) 59.4% <0.0001 
Self-report 6 17,397 0.95 (0.75, 1.20) 4.0% 0.39 
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By VMMC      
Genital examination  9 32,715 0.98 (0.90, 1.07) 0.0% 0.61 
Self-report  24 84,578 0.90 (0.84, 0.97) 62.1% <0.0001 
BY Exposure and Outcome 
measurement  
     
using genital exam and laboratory 
testing 
9 32,715 0.98 (0.90, 1.07) 0.0% 0.61 
One measured  18 67,181 0.93 ( 0.88, 0.99) 59.4% <0.0001 
Neither measured  6 17,397 0.95 (0.75, 1.20) 4.0% 0.39 
 
Notes: a. The study (Zeng et al., 2014) is an outlier. After deleting, the odds of HIV risk 
among insertive MSM were lower compared to the odds of HIV risk among MSM who 
primarily practice receptive or versatile sex positioning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Table 2: Database searching strategies using key words  
Search terms Search 
results 
#1   "HIV"[Mesh] OR "HIV"[tiab] OR "HIV Infections"[Mesh] OR "HIV 
Antibodies"[Mesh] OR HIV-1[tiab] OR HIV1[tiab] OR HIV-2[tiab] OR HIV2[tiab] OR 
"HIV/AIDS"[tiab] OR "Sexually Transmitted Diseases, Viral"[Mesh:NoExp] OR 
"human immunodeficiency virus"[tiab] OR "human immunedeficiency virus"[tiab] OR 
"human immune deficiency virus"[tiab] OR "AIDS"[tiab] OR "acquired 
immunodeficiency syndrome"[tiab] OR "acquired immunedeficiency syndrome"[tiab] 
OR "acquired immune deficiency syndrome"[tiab] 
381352 
 
#2 "Circumcision, Male"[Mesh] OR "Foreskin/surgery"[MeSH] OR circumcision[tiab] OR 
circumsie*[tiab] OR circumcis*[tiab]  
6693 
#3 "Homosexuality, Male"[Mesh] OR "Bisexuality"[Mesh] OR "gay men"[tiab] OR 
"bisexual men"[tiab] OR (bisexual*[tiab] AND men[tiab]) OR MSM[tiab] OR "men 
who have sex with men"[tiab] OR "Transgendered Persons"[Mesh] OR 
"Transsexualism"[Mesh] OR transgender*[tiab] OR intersex*[tiab]  
25012 
 
#4   #1 AND #2 AND #3  108 
#5  Limit #4 to: Publication date from 1980/01/01 108 
#6 newspaper article[pt] OR letter[pt] OR comment[pt] OR case reports[pt] OR practice 
guideline[pt] OR guideline[pt] OR news[pt] OR editorial[pt] OR historical article[pt] 
OR legal cases[pt] OR published erratum[pt] OR congresses[pt] 
3741476 
 
#7 #5 NOT #6 99 
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Table 3: Summary of Studies of Male circumcision status and HIV risk among men who have sex with men (ABS indicates an abstract only) 
Characteristics of included studies Total   
Sources  Study 
time and 
Location 
Race/ 
Ethnicity 
Age (yrs)  Participants: 
analytical/full 
sample 
HIV 
assessment 
N (%) 
Circumcision 
assessment 
N (%) 
Circumcise
d 
N (%) 
[HIV+/circ
+] 
Uncircumci
sed N (%) 
[HIV+/circ-
] 
Study 
design  
Sampling strategy  
Cross-sectional studies 
10
Qian, et al., 
2016 
Beijing, 
China, 
2010-
2011 
Asian 
Chinese 
Mean=31 1155 Lab: 
242/1155(21.0
%) 
Genital exam: 
79/964 (8.2%) 
11/79 
(13.9%) 
263/885 
(29.7%) 
Cross-
sectional 
Through a local 
community-based 
organization, 
advertisement on a 
website, outreach to gay-
friendly venues, 
snowball-sampling 
11
Crosby, et 
al., 2015* 
A mid-
size 
southern 
city, US, 
2011 
Black  Mean=22.6 
(SD=3.13) 
400 recruited,        
85 declined; 
Lab: 
106/384 
(27.6%) 
Self-report: 
279/384 
(72.7%) 
76/279 
(27.2%) 
30/105 
(28.6%) 
Cross-
sectional 
Convenience sampling 
from a HIV/STD clinic 
17
Solomon, et 
al., 
2014(ABS)* 
12 cities, 
India,    
2012-
2013 
Asian Indian Median=25 12022 Lab: 
838/12022 
(7.0%) 
Self-report: 
1963/12022 
(17%) 
104/1963 
(5.3%) 
734/10059 
(7.3%) 
Cross-
sectional 
Respondent-driven 
sampling  
12
Zeng, et al., Chengdu, 
China, 
Asian Median=26.
5 (Range 
570 Lab: 13.3% Genital 9/66 67/504 Cross- Stratified snowball 
56 
 
2014* 2009 Chinese 18-69) examination: 
all MSM 
(18.2%) 
(13.6%) (13.3%) sectional sampling  
20
Doerner, et 
al., 2013 
Britain, 
2007-
2008 
White Mean=36 
(Range 18-
75) 
1521 Self-reported: 
97/1097 
(8.8%) 
Self-report: 
254/1521 
(16.7%) 
 
Not 
reported 
Not reported Cross-
sectional 
Convenience sampling 
via website and venues 
(e.g., sexual health 
clinics, bars, clubs and 
others) 
13
Pando, et 
al., 2013* 
Buenos 
Aires, 
Argentina, 
Nov2007-
July2009 
Presumably 
Hispanic 
Mean=30.5 
(SD=11.5) 
482/500 
(96.4%) 
Lab: 
81/482 
(16.8%) 
Self-report: 
64/482 (13.4%) 
7/64 
(10.9%) 
74/418 
(17.8%) 
Cross-
sectional 
Respondent-driven 
sampling via website 
14
Zhou, et al., 
2013 
Chongqin
g, China, 
2010 
Asian 
Chinese 
Median=24 
(Range 18-
65) 
491/498 
(98.6%) 
Lab: 
All MSM 
(14.9%), 
bottom 
(14.9%), top 
(7.1%), 
versatile 
(16.7%) 
Self-report: 
88/498 (17.7%) 
Not 
reported 
Not reported Cross-
sectional 
Respondent-driven 
sampling via a STD 
clinic  
18
Schneider, 
et al., 2012 
South 
India,  
Aug 2008-
June 2009 
Asian Indian Median=26 
(Range 24-
30) 
387 Lab: 
72/387(18.6%) 
Self-report: 
143/397 
(36.9%) 
 
16/143 
(11.2%) 
56/188 
(29.8%) 
Cross-
sectional 
Convenience sampling 
from drop-in centers 
57 
 
22
Oster, et al., 
2011 
21cities, 
US,2008 
White (61%), 
Black (39%)  
White: 
Median=36, 
Black:  
Median=28 
5855 Lab: 
White 
561/3585 
(45.6%),  
Black 
619/2270 
(27.3%), 
Overall 
1180/5855(20.
2%) 
Self-report: 
4270/5181 
(82.4%) 
401/4270 
(9.4%) 
107/911 
(11.0%) 
Cross-
sectional 
Venue-based, time-space 
sampling  
25
Thornton, 
et al., 2011 
London, 
UK,2008 
Ethnic 
minority 
(17%) 
Median=39, 
(Range 20-
87) 
653 /689 
(94.8%) 
Self-reported: 
152/653(23.4
%) 
Self-reported: 
188/653 
(28.8%) 
35/188 
(18.6%) 
117/465 
(25.2%) 
Cross-
sectional 
Venue-based 
convenience sampling  
23
Jozkowski, 
et al., 2010 
US, 2009 Black (4%), 
White 
(82.1%), 
Hispanic 
(7.4%), Asian 
(2.9%), 
Others (3.1%) 
25159 (18-
23yr: 14.2%, 
24-
29:17.6%, 
30-39: 
22.9%, 40-
49: 27.7%, 
50-59: 
13.2%, 60+: 
3.4%) 
25159/26257 
(95.8%) 
Lab: 
14.1% 
Self-reported: 
21,312 (82.1%) 
3012/2131
2 (14.3%) 
543/3847 
(14.3%) 
Cross-
sectional  
Convenience sampling 
via email recruitment  
40
Lane, et al., 
2011 
Soweto, 
South 
Africa, 
2008 
Black African 64% are 
younger 
than 24 
363/387 
(93.8%) 
Lab: 
69/363 
(20.6%) 
Self-report: 
124/363 
(33.6%) 
Not 
reported 
Not reported Cross-
sectional 
Respondent-driven 
sampling 
58 
 
41
McDaid, et 
al., 2010 
Glasgow 
and 
Edinburgh
, Scotland, 
2008 
White Not reported 1405/1508 
(93.2%) 
Lab: 
54/1405 
(4.5%) 
Self-report: 
233/1405 
(16.6%) 
8/233 
(4.2%) 
46/1172 
(4.6%) 
Cross-
sectional 
Convenience sampling at 
gay venues 
36
Begley, et 
al., 
2008 
7 cities, 
US, 
2006 
White 
(55.9%), 
Black 
(25.4%), 
Hispanic 
(5.5%), 
Others 
(13.2%)  
Median=32, 
60% are 
older than 
25 
780/1050 
(74.3%) 
Self-report:  
100/772 (13%) 
Self-report 
646/772 (84%) 
81/646 
(13%) 
19/126 (15%) Cross-
sectional 
Convenience sampling 
via gay pride events 
27
Calzavara, 
et al, 
2007(ABS) 
 
 
Ontario, 
Canada, 
2001-
2005 
Native 
American 
(2%), 
Latino (4%), 
Others (9%), 
White (85%) 
Not reported 165 Not reported Self-report 
11/15 (73%) 
 
2/11 (18%) 2/4 (50%) Cross-
sectional 
Convenience sampling 
8
Millett et al, 
2007-Latino 
3 cities, 
US, 
May 
2005- 
Apr 2006 
Latino (49%) 
 
Median=33.
1 
957/1091 
(87.7%) 
Lab: 
348/957 (36%) 
Self-report: 
317/957 (33%) 
116/317 
(37%) 
232/640 
(36%) 
Cross-
sectional 
Respondent-driving 
sampling  
59 
 
8
Millett, et 
al., 
2007-Black 
3 cities, 
US, 
May 
2005- 
Apr 2006 
Black (51%) Median=42.
5 
1079/1154 
(93.5%) 
Lab: 
563/1154 
(52%) 
Self-report: 
794/1079 (74%) 
 
425/794 
(54%) 
138/285 
(48%) 
 
Cross-
sectional 
Respondent-driving 
sampling 
42
Mor, et al., 
2007 
San 
Francisco, 
US, 
Jan1996- 
Dec 2005 
White (66%), 
Latino (16%), 
Asian/PI 
(10%), 
Black (7%), 
1% Other 
Not reported 20 832 Lab: 
14902 (72%) 
Genital exam: 
15207/20832 
(73%) 
 
8942/12 
577 (71%) 
5960/8255 
(72%) 
Cross-
sectional 
Electronic medical 
records review 
44
Reisen, et 
al.,2007  
New York 
City, US 
Latino (146 
from Brazil, 
169 from 
Colombia, 
167 from 
Dominican 
Republic) 
Brazil: 
Mean=37.5; 
Colombia: 
Mean=38.2;  
Dominican 
Republic: 
Mean=33.6 
427/482 
(88.6%) 
Self-report: 
Brazilian 
(22.6%), 
Colombian 
(32.0%), 
Dominican 
(25.2%) 
Self-report: 
All (25%) 
Brazilian 
(20.6%), 
Colombian 
(26.6%), 
Dominican 
(25.8%) 
28/111 
(25.3%) 
101/336 
(30.1%) 
Cross-
sectional 
Convenience sampling 
31,32
Sanchez, 
et al., 
2007;2009 
3 cities in 
Peru, 1 
city in 
Ecuador, 
Presumably 
Hispanic 
Mean=26.4 
(SD=6.7) 
2884 Lab: 
314 (11%) 
Genital exam: 
123/2884 (4%) 
13/123 
(1%) 
301/2761 
(11%) 
Cross-
sectional 
Snowball sampling from 
Minister of Health clinics 
60 
 
Feb 2006- 
Jun 2006 
28
Lai, et al., 
2004 (ABS) 
Taipei, 
Taiwan, 
2003 
Presumably 
Asian 
Chinese 
Not reported 556 Lab: 
33/556 (6%) 
Self-report: 
154/556 (28%) 
5/154 (3%) 28/402 (7%) Cross-
sectional 
Not reported 
29
Kumta, et 
al., 
2002 (ABS) 
Mumbai, 
India, 
Mar 2001- 
Jul 2002 
Presumable 
Asian Indian 
Not reported 122 Lab: 
21/122 (17%) 
Genital exam: 
27/122 (22%) 
2/27 (7%) 19/95 (20%) Cross-
sectional 
Not reported 
45
Tabet, et 
al., 
2002 
Lima, 
Peru, 
1996 
Presumable 
Hispanic  
Mean=24 440/451 
(97.6%) 
Lab: 
82/444 
(18.5%) 
Genital exam: 
36/440 (8%) 
Not 
reported 
Not reported Cross-
sectional 
Convenience sampling 
via street-outreach  
43
Reid, et al., 
2001 
England 
and 
Wales, 
2001 
White (93%), 
Asian (3%), 
Mixed (2%), 
Black (1%) 
Mean=32.8 
(SD=10.5) 
13 851/14 616 
(94.8%) 
 
 
Self-report: 
726 
/13851(5%) 
Self-report: 
3089/13 851 
(22%) 
188/3089 
(6%) 
538/762 (5%) Cross-
sectional 
Convenience sampling 
via gay-focused event, 
booklets, and website 
39
Kreiss & 
Hopkins, 
1993 
Seattle, 
US, 
Apr 1989- 
1991 
White (90%), 
Black (4%), 
Latino (4%), 
Asian/PI 
UMC: 
Mean=40.6, 
MC: 
Mean=34.5 
499/502 
(99.4%) 
 
Lab: 
313/499 (63%) 
Self-report: 
422/499 (85%) 
254/422 
(60%) 
59/77 (77%) Cross-
sectional 
Convenience sampling 
via AIDS clinics 
61 
 
 (1%) 
Studies with follow-up 
19
Koblin, et 
al., 2013 
6 cities, 
US, 
2009-
2010 
Black  HIV-
negative: 
Mean=37  
1164 at 
baseline, 935 at 
6m, 872 at 12m 
Lab: 
28/1162 
(2.4%) 
Combination of 
genital exam 
and self-report: 
881/ 1162 
(75.8%) 
21/881(2.4
%) 
7/281 (2.5%) Cohort 
study 
with 
follow-up 
at  6m 
and 12m 
Convenience sampling  
at gay community and 
via sex networkers; part 
of the HPTN061 
16
Chen, et al., 
2011* 
Taiwan, 
2001-
2005 
Asian 
Chinese 
mean=32.4, 
sd=8.1, 
range 17-81 
1093 Lab: 
-all MSM 
(7.4%), -2001 
(3.4%), 
-2002 (5.1%), 
-2003 (8.9%), 
-2004(8.5), 
-2005 (8.3%) 
Self-reported: 
266/1024 
(26.0%) 
13/266 
(4.9%) 
66/758 
(8.7%) 
Follow-
up at 6m 
for HIV-
neg MSM 
for 4 
years 
Convenience sampling; 
recruit from VCT 
programs via 5 gay-
oriented-saunas  
21
Sanchez, et 
al., 2011 
US and 
Peru, 
2003-
2007 
Presumably 
Hispanic and 
White 
US: MC: 
Mean=30, 
UMC: 
Mean=27;  
Peru: MC: 
Mean=41,  
UMC: 
Mean=37  
1822/1824 
(99.9%): 1360 
(74.6%) from 
Peru, 
462(25.4%) 
from US 
Lab: 
83/1822 
(4.6%) 
Genital exam: 
All MSM: 
457/1822(25.7
%), US 
(81.8%), 
Peru (5.8%), 
18/457 
(3.9%) 
67/1365 
(4.9%) 
Follow 
up for 
18m at 
every 3m 
Part of a RCT for HSV-2 
suppression for HIV 
prevention (HPTN039) 
62 
 
 
37
Gust, et al., 
2010 
57 cities 
in US; 3 
cities in 
Canada; 1 
city in 
Netherlan
ds 
White (86%), 
Hispanic 
(6%), Black 
(4%), Asian 
(2%), Other 
(2%) 
UMC=36.9, 
MC=36.6 
4889/5417 
(90.3%) 
Lab: 
342/488 
(7.0%) 
Self-report: 
4209/4889 
(86.1%) 
299/4209 
(7.1%) 
43/680 
(6.3%) 
Follow 
up for 
36m at 
every 6m 
Part of a RCT for HIV 
vaccine 
38
Jameson, et 
al., 2010 
US, Oct 
2001-May 
2006 
Whites 
(75%), 
Hispanic 
(8%), Black 
(6%), 
Asian/PI 
(5.4%), Other 
(4.8%) 
75.7% older 
than 25 
years 
 
3828/4749 
(80.6%) 
Lab: 
1142/6924 
(16.5%) 
Genital exam : 
3241/3828 
(85%) 
1016/5843 
(17.4%) 
181/1081 
(16.7%) 
Follow-
up with 
1-6 visits 
Convenience sampling 
via STD clinics 
15,24,30
Buchbi
nder,2007; 
Koblin  et al., 
2012; 
Barnabas, et 
al., 2011 
North 
America, 
Caribbean
, South 
America, 
Australia, 
2004-
2007  
Black (10%), 
Latino (10%), 
Multiracial 
(25%), 
White (50%), 
Other (6%) 
 
Median=30 
(Range 18-
45) 
1787/1836 
(97.3%) 
Lab: 
80 (5%) 
Combination of 
self-report 
and genital 
exam: 
999/ 1787 
(56%) 
52/999 
(5%) 
 
 
28/788 (4%) Follow 
up at 
12,30 and 
52 w, and 
every 
26w 
afterward
s 
Double-blind 
randomized selection 
(STEP study) 
33,34
Templeto Sydney, Anglo 
ethnicity 
Median=35 
(Range 18-
1426/ 1427 Lab: Combination of 29/938 13/488 (3%) Follow-
up for 
Convenience sampling 
from  community-based 
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Notes:  
ABS: abstract; MC: male is circumcised; UMC: uncircumcised ; RCT: Randomized Control Trials; HPTN:  The HIV Prevention Trials Network;  VCT: Voluntary Counselling and Testing ;  
HSV-2: Herpes simplex virus type 2; PI: Pacific Islander 
*crude odds ratios were calculated by raw data  
n, 
et al., 
2009; Mao, 
et al., 2008  
Australia, 
2001-
2004 
 
(74%) 75) (99.9%) 
 
42 (3%) 
0.8/100 pyr 
self-report 
and genital 
exam: 
938/1426 (66%) 
(3%) 36m at 
every 6m; 
cohort 
study 
venues (HIM study);  
35
Bartholow, 
et al., 
2006 
US, 
Canada,  
Netherlan
ds 
Jun 1998- 
Nov1999 
Asian/PI 
(2%), 
Other (2%), 
Black (4%), 
Latino (6%), 
White (86%) 
Not reported 5090/5095 
(99.9%) 
 
Lab: 
2.8/100  pyr , 
362/5095 (7%) 
Self-report: 
4381/5090 (86) 
 
315/4381 
(7%) 
47/709 (7%) Follow-
up for 
36m 
Part of a RCT 
49
Buchbinder, 
et al., 2005 
6 cities, 
US, 
Apr 1995- 
May 1997 
White (76%), 
Latino (12%), 
Black (7%), 
Asian/PI 
(5%) 
65.4%  are 
older than 
35 
3257 
 
Lab: 
1.55/100 pyr 
Self-report: 
2866/3257 
(88%) 
 
 
Not 
reported 
Not reported Follow-
up for 
18m at 
every 6m 
Recruit from HIVNET 
program 
64 
 
CHAPTER V 
PREDICTING THE IMPACT OF VOLUNTARY MEDICAL MALE CIRCUMCISION 
ON HIV INCIDENCE AMONG MEN WHO HAVE SEX WITH MEN IN BEIJING, 
CHINA 
 
Abstract 
Objective: To project the number of new HIV cases over 11-year period among men who 
have sex with men with different assumptions of uptake of voluntary medical male 
circumcision (VMMC) in Beijing, China.  
Methods: Using a deterministic compartmental modeling procedure to fit prevalence 
from 2005-2015, we projected new HIV cases during 2016-2026 under different coverage 
rates ranging from 0.0001 (at baseline) to 0.15 (an optimistic assumption) with simulation 
on varying transmission rates, model calibration to match historical data, and sensitivity 
analyses for several assumptions.  
Results: Compared with the baseline (λ=0.0001), we found the new HIV cases would 
reduce with the increase of coverage rates of the VMMC among MSM. The higher the 
coverage rate, the lower new HIV cases would be. The number of new HIV cases would 
keep decreasing by 0.15%, 0.80%, 1.6%, 7.1%, 12.4% and 16.3% compared to the 
baseline by the end of 2026, if we increase the annual coverage rate of VMMC to 0.01, 
0.005, 0.01, 0.05, 0.1 and 0.15, respectively. 
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Discussion: As one of the first studies to model the potential impact of VMMC among 
MSM in China, our model suggested a modest to significant public health impact of 
VMMC. Even at just 15% VMMC annual uptake rate, the reduction in new infections is 
substantial. Therefore, there is a strong need to determine the efficacy of VMMC among 
MSM, to improve the evidence base for its potential use among MSM in low 
circumcision settings. Only then can policymakers decide whether to incorporate VMMC 
into a package of HIV prevention interventions targeting MSM.   
Key words: Voluntary medical male circumcision; mathematical modeling; HIV; 
incidence; men who have sex with men; China  
Introduction 
     Based upon a newly released report from the Chinese government, the number of 
people living with HIV/AIDS (PLWHA) in China was 575,000 by the end of 
2015(ChinaDaily, 2015). Although national HIV surveillance data suggest that China is a 
relatively low-prevalence country, the trend of increasing HIV prevalence among men 
who have sex with men is of concern (NHFPC, 2014, 2015).   
     The most common transmission route for the HIV/AIDS epidemic in China has 
shifted from injection drug use and contaminated plasma collection/reinfusion in the 
1990s to unprotected sexual contacts in the early 21
st
 century (Guo et al., 2011; UNAIDS 
& MoH, 2015). The rapid increase in male-to-male sexual transmission is of a particular 
concern (Chow et al., 2011a; Lu et al., 2013; J. R. Wu et al., 2013; Ye et al., 2012). 
Although the dominant route is still reported to be heterosexual transmission, male 
homosexual transmission shows a marked uptrend, representing just 2.5% of new 
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infections in 2006 to 25.8% in 2014 (NHFPC, 2014, 2015). In addition, homophobia and 
stigma against MSM is significant in China, and its MSM epidemic is very likely to be 
underestimated (Lou et al., 2014; Z. Wu et al., 2013; Y. Zhou et al., 2014). 
     Although the ever-increasing HIV epidemic explodes among Chinese MSM, few 
effective interventions are available and/or widely utilized (Guo et al., 2011). Condoms 
can effectively prevent HIV transmission, but only 20% MSM consistently use condoms 
during sexual activities (Guo et al., 2011; Zheng, 2009). Pre-exposure prophylaxis (PrEP) 
can be used by uninfected MSM, but uninfected individuals often fail to adhere to pre-
exposure prophylaxis (PrEP) antiretroviral drug regimens when they do not feel ill nor 
perceive themselves to be at high risk. PrEP adherence is limited by drug side effects 
(Huang et al., 2014; Okwundu, Uthman, & Okoromah, 2012; Pretorius, Stover, Bollinger, 
Bacaer, & Williams, 2010). Voluntary medical male circumcision (VMMC) might serve 
as a biomedical tool to provide lifelong protection after a single surgical procedure for 
MSM, as has been demonstrated for heterosexual men (Vermund & Qian, 2008).  
     Circumcision is likely to protect men from acquiring HIV by eliminating the most 
vulnerable mucosal surface areas and HIV target cells in a minimally keratinized zone, 
the inner surface of the penile prepuce (Donoval et al., 2006; Vermund & Qian, 2008). 
Both observational studies and large randomized controlled trials (RCT) have shown that 
VMMC reduces the risk of HIV acquisition by over half in heterosexual men living in 
high prevalence areas of Africa (Auvert et al., 2005; Bailey et al., 2007; R. H. Gray, 
Kigozi, et al., 2007). Although the evidence on the relationship between VMMC and HIV 
risk among MSM has been inconclusive, protective effects have more often been 
observed among men who practiced insertive sex (Beyrer, 2010a; Doerner et al., 2013b; 
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Fankem et al., 2008; Gust et al., 2010; Jameson et al., 2010a; Jozkowski et al., 2010; 
Londish et al., 2010b; Sanchez et al., 2011; Schneider et al., 2012b; Wiysonge et al., 
2011; C. Zhou et al., 2012). A study published in 2015 among MSM in Beijing suggested 
a remarkably strong protection effect among Chinese MSM who predominately practice 
insertive sex (adjusted odds ratio [aOR], 0.15; 95% confidence interval [CI], 0.04-0.65). 
This study confirmed all circumcisions by physical examination and suggested a strong 
beneficial trend for MSM with versatile or receptive sexual positioning as well, providing 
the strongest evidence to date that VMMC might be a useful biomedical tool for HIV risk 
reduction among MSM. Our recently conducted meta-analysis revealed a statistically 
significant protective effect against HIV among MSM, especially among MSM with 
comparatively lower risk profiles, such as MSM in Asia (Zhang, Qian, et al., Under 
review). Therefore, circumcision may prove to be an overlooked biomedical tool for HIV 
prevention among MSM.  
     To date, only one paper adopting a stochastic network-based model employing 
hypothetical sex-role preferences has been published which concluded that the roll-out of 
VMMC among MSM would be unlikely to reduce new HIV infection in Peru 
substantially (Goodreau et al., 2014). However, Goodreau et al (2014) employed older, 
less optimistic assumptions as to VMMC protective efficacy, not compatible with more 
recent literature (Goodreau et al., 2012; Qian et al., 2016; Zhang, Qian, et al., Under 
review). Furthermore, the Peru and China MSM epidemics are different in several 
epidemic and social characteristics, limiting their model’s relevance for Chinese settings. 
Lou et al have assessed the impact of a few behavioral intervention approaches (e.g., 
condom use, partner reduction, HIV testing and ART) among Chinese MSM in Beijing 
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using mathematical modeling strategies (Lou et al., 2014; Lou, Wu, Chen, Ruan, & Shao, 
2009). Neither the Peru nor China studies specifically examined the putative impact of 
VMMC among MSM in China.  
     We sought to model the extent to which VMMC could alter the MSM epidemic in 
Beijing, China, employing a deterministic compartmental modeling strategy to project 
new HIV cases from 2016 to 2026 among MSM under different assumptions, particular 
the uptake rates of VMMC and degree of protective efficacy of VMMC. We 
hypothesized that projected HIV incidence among MSM in Beijing would be reduced by 
greater use of VMMC. In the current study, we aimed to establish a more generic 
mathematical model that can be generalizable to other settings with comparable social 
and cultural characteristics.  
Methods 
Study design 
     We used a deterministic compartmental model for simulating and projecting the 
HIV epidemic among MSM in Beijing. Deterministic compartmental models can specify 
transmission rates between compartments (e.g., susceptible, infectious) and they fit well 
large populations (R. Barnabas, 2016; Trottier & Philippe, 2000 ). This model is usually 
used to describe and explain transmission patterns of certain infectious diseases at the 
population scale (Trottier & Philippe, 2000 ). In the current study, we did not employ the 
sex-role-preference model as the sex position was too dynamic to capture (Goodreau et 
al., 2014; Lou et al., 2009; Wiysonge et al., 2011). Although some MSM in Beijing have 
female sexual partners, they were less likely to engage risky sexual behaviors with their 
female partners (Lou et al., 2014; Lou et al., 2009). Therefore, we only considered the 
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HIV infection as the result of homosexual contacts with male partners no other route of 
transmission was interfered in the current study (Fan et al., 2012; Lou et al., 2014). 
Model parameters (e.g., demographics, behavioral and population-level) of the 
compartmental ordinary differential equation model were informed by key factors 
identified in published literature and available datasets. 
     In order to capture the randomness of transmission rates, we further simulated the 
transmission rates by 50 times using linear coefficients to capture all possible 
possibilities. We also assumed that the active age of sexual activities ranges from 18-65 
years among MSM in Beijing (Li, Liang, & Yang, 2008; Lou et al., 2014). 
Model structure 
     As being circumcised may change the risk of HIV transmission significantly among 
MSM (Goodreau et al., 2014; Goodreau et al., 2012; Qian et al., 2015), the study 
population was divided into two mutually exclusive subgroups: 1) uncircumcised MSM 
and 2) circumcised MSM. In this model, seronegative MSM were entered into the overall 
MSM population with a rate of σ (the susceptible population); σ+ represented the rate 
entering the circumcised susceptible pool (Sc+), while σ
-
 represented the rate entering the 
uncircumcised susceptible pool (Sc-). Meanwhile, MSM could leave the transmission 
model by aging beyond 65 years, emigrating out of Beijing, or by dying. We used the 
parameter τ to indicate rates of leaving the model among susceptible MSM, with τ+ 
representing the rate of leaving the circumcised susceptible pool (Sc+) and τ
-
 representing 
the rate of leaving the uncircumcised susceptible pool (Sc-). MSM would change from 
being uncircumcised to being circumcised at a rate of λ (Figure 1). 
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     Uncircumcised MSM became infected and entered the compartment of HIV-
infected without circumcision (Ic-) at an HIV transmission rate of ρ
-
; and circumcised 
MSM became infected (Ic+) at a transmission rate of ρ
+
. Both circumcised and 
uncircumcised MSM could leave the infectious pool at a rate of 𝜂− for uncircumcised and 
 𝜂+ for circumcised MSM for the following reasons: 1) progression to AIDS, 2) death 
due to HIV infection, 3) having undetectable viral loads due to either being an elite 
immunologic controller (e.g., a small group of HIV-infected patients who can maintain a 
high level of CD4 cell counts without progressing immunologically towards AIDS over 
years in absence of ART (Pantaleo et al., 1995)) or adhering to an effective ART regime 
(Figure 1). When possible, parameters were estimated from the published literature or 
from available unpublished data sources (Lou et al., 2014; Lou & Smith, 2011; Lou et al., 
2009); a few parameters were calculated within the model itself (Table 1). 
Model calibration 
     In order to refine the model to provide the most valid predictions, we used data to 
calibrate the model parameters to enable the model to predict historical surveillance data. 
At the initial stage, we used 2005-2015 surveillance data for HIV prevalence in Beijing to 
compare trends with those predicted by our model (Figure 2). In this model calibration 
process, parameters were adjusted until the prediction lines best overlapped with lines 
that reflected the historical surveillance data. When the prediction model overlapped with 
the surveillance data, using plausible and defensible parameter estimations, we 
considered the generated model to serve well for predictions forward in time. 
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     In Figure 2, we presented the prediction model that we used for further calculations; 
the predicted and historical lines among four groups of MSM (susceptible circumcised 
[Scm], susceptible uncircumcised [Scp], infected circumcised [Ichp], and infected 
uncircumcised [Ichm]) overlapped well with each other. After this initial model 
calibration, we used the numbers generated by the model for 2015 (e.g., ρ-= 0.0099861, 
ρ+= 0.0093921, Scm=362,476, Scp=6,970, Ichp=59, and Ichm=3,129) as the baseline 
initial state to predict numbers of infected and susceptible MSM from 2016 to 2026 (see 
Appendix 1 for detailed formulas). 
Data sources and estimation 
(1) Calculation of HIV incidence rates among both circumcised and uncircumcised MSM 
(2005-2015): To calculate incidence rates among circumcised and uncircumcised MSM 
for 2005-2015, we used a pooled adjusted odds ratio from a recently updated meta-
analysis(Zhang, Qian, et al., Under review) as well as the HIV surveillance data from 
China CDC (personal communication). As these data were only available as summary 
statistics, no identifiers can be found to track back to individual subjects in the HIV 
surveillance system. We calculated the HIV incidence from 2005-2015 among 
circumcised and uncircumcised MSM in Beijing (Table 2; see Appendix 2 for details of 
these calculations).  
(2) Simulation for incidence rates of HIV among both circumcised and uncircumcised MSM 
(2016-2025): To simulate HIV incidence from 2016 through 2025, we used existing 
incidence data among circumcised and uncircumcised MSM (2005-2015).  We conducted 
a series of simulations for transmission rates of HIV among circumcised (ρ+) and among 
uncircumcised (ρ-) men. The simulation procedure is to project future transmission rates 
72 
 
based upon existing HIV incidence among MSM for the next 10 years (R-software, 
Murray Hill, NJ, USA). We assume that incidence would increase linearly. Through 50 
repeated simulations, we generated the predicted transmission rates for 2016-2025 among 
uncircumcised and circumcised MSM (Figure 3; Table 3).  
(3) Prediction of new HIV cases: Using the calibrated model as well as the simulated data, 
we calculated new HIV cases among MSM for each prediction year (2016-2026) by 
varying the annual coverage rates of VMMC from 0.0001 to 0.15. We compared the new 
HIV cases for each hypothetical scenario with the new HIV cases at the baseline 
(λ=0.0001). The reduced proportion of HIV-infected men was defined as “the (HIV cases 
in the predicted year minus the number of cases at baseline) divided by the baseline 
cases”. This was used as the indicator for each hypothetical coverage rate comparing the 
projected date with the baseline infection rate.   
(4) Sensitivity analyses: We conducted sensitivity analyses by setting the transmission rates 
for both circumcised and uncircumcised MSM at the same level as the incidence rate seen 
in 2015. If nothing changes from 2015, it represents a lower bound for the transmission 
rate. In addition, we calculated new HIV cases with a range of protective efficacies 
ranging from 0.07 (95% CI, 0.01-0.12) to 0.47 (95% CI,-0.02-0.73) as literature 
suggested (Qian et al., 2016; Zhang, Qian, et al., Under review).  
Results 
New HIV cases at each different coverage rate of VMMC 
     Compared with the baseline (λ=0.0001), we found the new HIV cases reduced with 
increasing coverage rates of the VMMC among MSM. Higher coverage rates are 
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associated with lower numbers of HIV new case. By the year 2026, retaining the VMMC 
coverage rate at the baseline 2015 rate (λ=0.0001), new HIV cases are 50,301, while a 
small increase of VMMC coverage to 0.0005 results in the number of HIV cases to be 
reduced slightly to 50,270. Similarly, by the end of 2026, the number of newly infected 
HIV cases decreases by 0.15%, 0.8%, 1.59%, 7.11%, 12.38% and 16.34% compared to 
the baseline (λ=0.0001) if we increase the annual coverage rate of VMMC to 0.01, 0.005, 
0.01, 0.05, 0.1 and 0.15, respectively (Table 4).  
     With the increased coverage rates of VMMC, the absolute number of infected 
circumcised MSM increases (Figure 4a), while the number of infected uncircumcised 
MSM decreases over the same period of time (Figure 4b).  With the increased coverage 
rates of VMMC, the number of susceptible circumcised MSM increases each year, given 
the larger pool of circumcised men (Figure 5a), while the number of susceptible 
uncircumcised MSM decreases over the same period of time (Figure 5b). Still, the risk of 
transmission is lower for the circumcised (ρ+) than among uncircumcised (ρ-) men, as per 
assumptions (see Methods).  
Prevalence of VMMC among MSM 
     We also hypothesized the prevalence of VMMC among all MSM in Beijing. With a 
higher coverage rate, the prevalence of VMMC naturally increased accordingly. By the 
year of 2026, the prevalence increased from 1.75% when the baseline coverage rate was 
0.0001 to 58.76% when the VMMC coverage rate increased to 0.15 per annum (Table 5).  
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 Results of the sensitivity analyses  
     The same patterns for HIV-infected and susceptible MSM by circumcision status 
and proportion of circumcised men were observed when the transmission rates were set at 
the same incidence rate seen in 2015. In addition, a smaller magnitude of the reduction in 
the proportion of HIV-infected men with increasing circumcision coverage was observed 
(Supplementary Table 1; Supplementary Figure 2a-d).  
     We also assessed the HIV incidence by different protective efficacies ranging from 
being very conservative 7% (Zhang, Qian, et al., Under review) to being optimistic 
47%(Qian et al., 2016). The transmission rate of HIV reduced among circumcised MSM 
with higher circumcision coverage rates (Supplementary Figure 3). Overall, fewer new 
HIV cases were observed with higher protective efficacies within the same circumcision 
coverage rate. The higher coverage rate, the fewer HIV cases would be in the projected 
years (Supplementary Table 2).   
Discussion 
     We have employed a deterministic, compartmental model to predict the magnitude 
of the impact of VMMC on HIV acquisition over a 11-year period by estimating the 
reduction in proportion of HIV-infected cases (Kripke et al., 2016). By changing the 
coverage rates of VMMC from the very low baseline coverage (λ=0.0001) to a 
hypothetical scenario of an active VMMC program (λ=0.15), our model suggested a 
modest to significant public health impact of VMMC for MSM in China, depending on 
coverage assumptions, given an assumed efficacy of 7%. This low efficacy was derived 
from a systematic review and meta-analysis, but a 47% (95% confidence interval: -2 to 
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+73%) protective efficacy estimate from a Chinese study conducted in 2010-2011 
suggested VMMC to be more beneficial than earlier studies suggested; our estimates of 
benefit are very conservative (Qian et al., 2016; Zhang, Qian, et al., Under review). The 
reduction in proportion of HIV-infected cases ranged from 0.06% when the VMMC 
coverage rate as low as 0.0001 (corresponding to the prevalence of VMMC as 1.7%) to 
16.3% when the VMMC coverage rate increased to 0.15 (corresponding to the prevalence 
of VMMC as 58.8%) by the year of 2026. Meanwhile, we observed a big jump of the 
reduction in the proportion of the number of HIV cases (from 1.6% to 7.1%) when the 
VMMC coverage rate increased from 0.01 to 0.05. The big jump may indicate that a 
slight increase of the VMMC coverage rate may result in a significant reduction in new 
HIV cases among MSM in China, even with our use of very conservative estimates of the 
efficacy of VMMC in protecting MSM.   
     A seemingly paradoxical finding is easily explained.  With the increased coverage 
rate of VMMC, the number of circumcised MSM increasing over time increases both the 
number of  susceptible and infected circumcised men over time, merely because they are 
greater in number and we assume the very modest 7% protective efficacy. In parallel, the 
number of uncircumcised MSM who are either infected or are susceptible decreases over 
the same period of time, as they are overall reduced in number with increased 
circumcision coverage.  
     Compared with modeling estimates using data from Peru and from more resource-
rich settings (Anderson et al., 2009; Goodreau et al., 2014; Njeuhmeli et al., 2011), our 
model suggests a more optimistic efficacy of VMMC among MSM, even when using a 
low protective efficacy estimate (7%) for VMMC. In the study conducted in Peruvian 
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MSM, authors observed less than 5-10% of HIV cases to be likely averted if VMMC 
coverage rate were to grow to 50% in coming years (Goodreau et al., 2014). Two other 
studies posited that only if a 100% coverage rate of VMMC were achieved would such an 
incidence reduction be observed (Anderson et al., 2009; Londish, Templeton, Regan, 
Kaldor, & Murray, 2010a). The proportion of MSM who have a comparatively lower-risk 
profile, the low baseline VMMC prevalence, and the relatively recent expansion of the 
HIV epidemic among MSM in China may suggest, in part, why our model is more 
optimistic about the VMMC role for MSM in China (Lou et al., 2014; Vermund & Qian, 
2008; Zhang, Qian, et al., Under review). As a “surgical HIV vaccine" that offers lifelong 
protective benefits, VMMC might be embraced by the MSM community if advocated for 
by public health and community-based representatives. A clinical trial to estimate more 
precisely the protective efficacy of VMMC in men who practice predominantly insertive, 
versatile, or receptive anal intercourse would help refine projection models considerably.   
     Strengths of the current study include our employment of a deterministic 
compartmental model for predictions. The deterministic model has advantages compared 
to stochastic models for predicting incidence of chronic infectious diseases such as 
HIV/AIDS (Lou et al., 2014). Although the output of a deterministic model was fully 
determined by values of included parameters and initial conditions, the simulation 
procedure for transmission rates can capture randomness properties better than can 
stochastic models (Vynnycky & White, 2010). Additionally, we used sensitivity analyses 
to estimate new HIV cases at their lower bound when transmission rates remained the 
same as seen in 2015 as well as at different protective efficacies, suggesting our findings 
to be robust and plausible. Our model may apply, too, to other settings with similar 
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epidemic characteristics. A second strength of our study is that, unlike other modeling 
studies using hypothetical/simulated data (Goodreau et al., 2014), we used validated data 
sources to calculate parameters while adjusting initial conditions for the model (Lou et 
al., 2014; Zhang, Qian, et al., Under review). The simulation procedure used parameters 
estimated from HIV surveillance data in Beijing, improving the validity of the model and 
likely accuracy of context-specific predictions. Third, during the model building 
procedure, we gradually raised the VMMC coverage rates from baseline (λ=0.0001) to 
multiple hypothetical situations until λ=0.15. This procedure captures the slight changes 
as the result of the increased VMMC coverage rate, providing a range of estimates and 
practical guidance for health professionals for future interventions of VMMC among 
MSM in China.   
     The major limitation of our prediction model is a simplification of the real epidemic 
in Beijing in our effort to balance parsimony and reality. For instance, unlike existing 
studies considering sexual role preferences (Goodreau et al., 2014; Lou et al., 2014), we 
did not stratified Chinese MSM by their sex role positioning due to the lack of 
population-based information as the relative frequencies of these sexual positioning 
preferences. However, as our prediction model was built upon average transmission rates 
regardless of sexual positioning, it may capture average transmission patterns among 
MSM as a whole in Beijing.  We did not incorporate other risk factors (e.g., types of 
partners, multiple partnership, and condom use) in the model. With more availability of 
the epidemic information among this population, a more sophisticated model can emerge 
to assess the impact of VMMC on curbing HIV among Chinese MSM.    
78 
 
     In conclusion, our model estimates the potential benefit of VMMC among MSM in 
China, using conservative to optimistic estimates of the efficacy of VMMC for HIV 
prevention. VMMC may serve as a new tool to reduce HIV incidence among MSM in 
China. Although the optimal scenario of higher VMMC coverage rates can bolster HIV 
incidence reduction among MSM, the lack of an efficacy trial in this population limits 
our ability to confidently assert the impact of VMMC on HIV, since protective efficacy 
of VMMC may vary greatly by epidemic context and relative frequency of predominantly 
insertive vs. receptive men.  Without such efficacy data, widespread VMMC could be 
logically, ethically, and economically challenging (Sullivan et al., 2014). 
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Figure 4. Schematic diagram for the HIV transmission model and voluntary medical 
male circumcision among men who have sex with men  
 
 
 
 
 
 
 
 
Equations from the diagram 
• 𝑆𝑐
−′(𝑡) = 𝜎− − 𝜌− ∗ 𝑆𝑐
−(𝑡) − 𝜆 ∗ 𝑆𝑐
−(𝑡) − 𝜏− ∗ 𝑆𝑐
−(𝑡) 
• 𝑆𝑐
+′(𝑡) = 𝜆 ∗ 𝑆𝑐
−(𝑡) − 𝜌+ ∗ 𝑆𝑐
+(𝑡) − 𝜏+ ∗ 𝑆𝑐
+(𝑡) + 𝜎+ 
• 𝐼𝑐
−′(𝑡) = 𝜌− ∗ 𝑆𝑐
−(𝑡) − 𝜂− ∗ 𝐼𝑐
−(𝑡) 
• 𝐼𝑐
+′(𝑡) = 𝜌+ ∗ 𝑆𝑐
+(𝑡) − 𝜂+ ∗ 𝐼𝑐
+(𝑡) 
•  
*parameters ρ+/ρ- are transmission rates.  
* parameter 𝜆 will be changed based upon different coverage 
of VMMC  
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Figure 5. Compare the model-predicted and historical trends (surveillance statistics) 
among four groups of men who have sex with men in China (2005-2015)  
 
 
NOTE: Figure 2 compares 2005-2015 surveillance data for HIV prevalence in Beijing 
(red line) with data predicted by our model (blue line); Scm: susceptible circumcised, 
Scp: susceptible uncircumcised, Ichp: infected circumcised, Ichm: infected 
uncircumcised; t: in years (from the year of 2005 to the year of 2015) 
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Figure 6. HIV transmission rates among circumcised (circ+) and uncircumcised 
(circ-) men who have sex with men in China 
 
 
Figure 7. Number of infected circumcised men who have sex with men in Beijing by 
years (2016-2026) 
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Figure 8. Number of infected uncircumcised men who have sex with men in Beijing 
by years (2016-2026) 
 
 
 
Figure 9. Number of susceptible circumcised men who have sex with men in Beijing 
(2016-2026) 
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Figure 10. Number of susceptible uncircumcised men who have sex with men in 
Beijing (2016-2026) 
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Table 4: Parameters for model building to assess HIV transmission model and the potential effect of 
male circumcision at varying levels of coverage among Chinese men who have sex with men   
Parameters Description Types Sources 
σ+ Recruitment rate into 
circumcised per year 
actual number 
/year 
(Lou et al., 2014; Lou 
et al., 2009) 
σ- Recruitment rate into 
uncircumcised per year 
actual 
number/year 
(Lou et al., 2014; Lou 
et al., 2009) 
τ+/τ- Natural removal rate from 
susceptible circumcised 
MSM 
Fraction (Lou et al., 2014; Lou 
et al., 2009) 
Death rate 0.01 actual 
number/year 
(Lou et al., 2014; Lou 
et al., 2009) 
emigration 
rate out of BJ 
0.06 actual 
number/year 
(Lou et al., 2014; Lou 
et al., 2009) 
ρ+ Transmission rate from 
susceptible to HIV positive 
among circumcised MSM-
overall 
Fraction Surveillance data 
from China CDC; 
Zhang et al., under 
review 
ρ- Transmission rate from 
susceptible to HIV positive 
among uncircumcised 
MSM-overall 
Fraction Surveillance data 
from China CDC 
λ Rate of circumcision 
among susceptible MSM 
per year 
Fraction Based upon different 
values given to λ 
ƞ+/ƞ- Rate of removal  from the 
infected 
circumcised/uncircumcised 
MSM group 
Fraction (Lou et al., 2014; Lou 
et al., 2009); model 
adjustment* 
yearly 
mortality rate 
due to AIDS 
Yearly death rate yearly mortality 
rate 
(Lou et al., 2014; Lou 
et al., 2009); model 
adjustment* 
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undetectable 
rate after ART  
Effective treatment that 
moves MSM out of the 
infectious pool  
undetectable rate  (Lou et al., 2014; Lou 
et al., 2009); expert 
opinion 
undetectable 
rate due to 
elite 
immunological 
control 
Inherent ability of the host 
immune system to reduce 
viral load 
undetectable rate (Okulicz & Lambotte, 
2011) 
emigration 
rate out of BJ 
Demographic factors of 
mobility after HIV 
infection  
emigration rate 
out of BJ 
(Lou et al., 2014; Lou 
et al., 2009) 
Scm Susceptible uncircumcised 
MSM (C-minus) 
Actual Number  Model predictions 
Scp Susceptible circumcised 
MSM (C-plus) 
Actual Number  Model predictions 
Ichp Infected circumcised MSM 
(C-plus) 
Actual Number  Model predictions 
Ichm Infected uncircumcised 
MSM (C-minus) 
Actual Number  Model predictions 
*Parameter was adjusted in order that the model could predict historical data
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Table 5: Prevalence and incidence among circumcised and uncircumcised MSM in Beijing, China 
(2005-2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Year  2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Uncircum-
cised MSM 
Incidence  0.00019 0.00054 0.00084 0.00099 0.00152 0.00197 0.00361 0.00563 0.00684 0.00883 0.00999 
Prevalence  0.00306 0.00868 0.0135 0.01588 0.02432 0.0315 0.05784 0.09009 0.10939 0.14134 0.15978 
Circumcised 
MSM 
Incidence  0.00018 0.0005 0.00079 0.00092 0.00142 0.00184 0.00338 0.00527 0.00641 0.0083 0.00939 
Prevalence  0.00294 0.00833 0.01297 0.01525 0.02337 0.03028 0.05565 0.0868 0.10548 0.13646 0.15437 
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Table 6: Actual and predicted HIV transmission rates among circumcised and 
uncircumcised men who have sex with men in China 
 Year Transmission rate for circ- 
(uncircumcised MSM) 
Transmission rate for circ+ 
(circumcised MSM) 
Actual 
transmission 
rates for 
2005-2015 
2005 0.0001913 0.00017795 
2006 0.0005424 0.000504712 
2007 0.0008438 0.000785447 
2008 0.0009924 0.000923922 
2009 0.0015198 0.001415785 
2010 0.0019689 0.001835104 
2011 0.0036149 0.0033755 
2012 0.0056309 0.005269953 
2013 0.006837 0.00640751 
2014 0.0088337 0.008297409 
2015 0.0099861 0.009392091 
Predicted 
transmission 
rates for 
2016-2025 
2016 0.0116339 0.010932 
2017 0.0132703 0.012472 
2018 0.0147111 0.013827 
2019 0.0161193 0.015152 
2020 0.0178254 0.016758 
2021 0.0193403 0.018184 
2022 0.0207475 0.019507 
2023 0.0222659 0.020936 
2024 0.0237391 0.022322 
2025 0.0254127 0.023898 
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Table 7. The number of newly infected HIV cases among men who have sex with men in 
China with different coverage rates of voluntary medical male circumcision (2016-2026) 
 
 
 
 
 
 
 
 
 
 
 
 
Year  
 
 
Circumcision 
coverage rate 
 
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Reduction in 
proportion 
HIV-infected 
with increasing 
circumcision 
coverage (%) 
λ1=0.0001 3188 6344 9816 13581 17547 21688 26104 30694 35397 40242 45190 50301 Baseline 
λ1=0.0005 3188 6344 9816 13580 17546 21685 26099 30687 35386 40225 45167 50270 0.06 
λ1=0.001 3188 6344 9815 13580 17543 21679 26090 30673 35366 40199 45132 50224 0.15 
λ1=0.005 3188 6343 9812 13570 17524 21644 26031 30582 35233 40013 44881 49897 0.80 
λ1=0.01 3188 6343 9809 13560 17501 21603 25961 30472 35073 39788 44577 49499 1.59 
λ1=0.05 3188 6337 9779 13476 17322 21279 25427 29656 33897 38170 42431 46724 7.11 
λ1=0.1 3188 6330 9744 13380 17122 20923 24853 28800 32696 36553 40331 44074 12.38 
λ1=0.15 3188 6324 9711 13292 16943 20614 24368 28094 31726 35279 38716 42081 16.34 
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Table 8. Prevalence of voluntary medical male circumcision among all men who have sex 
with men in Beijing by years (2016-2026) (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coverage  
rates/year 
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
λ1=0.0001 1.87 1.85 1.83 1.82 1.80 1.79 1.78 1.77 1.76 1.75 1.74 
λ1=0.0005 1.90 1.92 1.93 1.94 1.95 1.95 1.96 1.97 1.97 1.98 1.98 
λ1=0.001 1.95 2.00 2.05 2.09 2.13 2.16 2.19 2.21 2.23 2.26 2.27 
λ1=0.005 2.31 2.69 3.02 3.30 3.56 3.79 3.99 4.17 4.33 4.47 4.60 
λ1=0.01 2.77 3.54 4.21 4.80 5.32 5.78 6.19 6.56 6.88 7.17 7.43 
λ1=0.05 6.32 10.06 13.25 15.98 18.33 20.37 22.14 23.68 25.03 26.20 27.23 
λ1=0.1 10.58 17.61 23.36 28.13 32.10 35.44 38.24 40.61 42.61 44.30 45.72 
λ1=0.15 14.64 24.52 32.29 38.49 43.49 47.53 50.81 53.47 55.63 57.37 58.76 
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Figure 11.The extreme situation that the HIV incidence becomes stables after the 
year of 2015 
 
For the second scenario, we assume the transmission rates remain stable after the year of 
2015. By doing this, we can calculate the HIV prevalence in extreme situations (Figure 
3b).  
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Table 9. Results from mathematical modeling of predicting new HIV cases at 
different voluntary medical male circumcision coverage rates among men who have 
sex with men in Beijing (Flat rates, remain the same for the next 10 years)  
 
 
 
 
 
 
 
 
 
 
Year  
 
 
Circumcision 
coverage 
rate  
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Reduction in 
proportion 
HIV-infected 
with 
increasing 
circumcision 
coverage (%) 
λ1=0.0001 6344 9226 11864 14284 16511 18565 20465 22228 23868 25399 26832 baseline  
λ1=0.0005 6344 9226 11862 14282 16508 18561 20460 22221 23859 25388 26818 0.05 
λ1=0.001 6344 9225 11862 14280 16505 18555 20452 22210 23845 25371 26797 0.13 
λ1=0.005 8895 11486 13863 16048 18062 19922 21644 23242 24730 26117 27416 -2.18 
λ1=0.01 6343 9220 11847 14251 16454 18477 20338 22053 23637 25103 26462 1.38 
λ1=0.05 6337 9194 11781 14123 16238 18149 19870 21418 22809 24057 25174 6.18 
λ1=0.1 6330 9163 11706 13979 16002 17795 19377 20765 21977 23029 23938 10.79 
λ1=0.15 6324 9135 11638 13852 15797 17495 18968 20236 21319 22234 23003 14.27 
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Figure 12. HIV cases among circumcised men who have sex with men at different coverage 
rates of voluntary medical male circumcision (2016-2026) 
 
 
Figure 13. HIV cases among uncircumcised men who have sex with men at different 
coverage rates of voluntary medical male circumcision (2016-2026) 
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Figure 14. Susceptible circumcised men who have sex with men at different 
voluntary medical male circumcision coverage rates (2016-2026) 
 
 
Figure 15. Susceptible uncircumcised men who have sex with men at different 
voluntary medical male circumcision coverage rates (2016-2026) 
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Figure 16. Transmission rates among uncircumcision and circumcised MSM by 
different protective efficacies (7% to 47%) (Linearly increased transmission rates) 
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Table 10. New HIV cases with different protective efficacy of VMMC (2016-2025 projection) 
λ1=0.0001 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 36 37 38 39 40 40 41 42 43 44 45 45 
total # of new HIV cases 3188 6344 9816 13581 17547 21688 26104 30694 35397 40242 45190 50301 
17% efficacy             
# of new VMMC per year 36 37 38 39 39 40 40 41 41 42 42 42 
total # of new HIV cases 3188 6338 9804 13562 17522 21656 26065 30648 35344 40181 45121 50225 
27% efficacy             
# of new VMMC per year 36 37 38 39 39 40 40 41 41 42 42 42 
total # of new HIV cases 3188 6332 9791 13543 17495 21622 26023 30599 35287 40116 45048 50144 
37% efficacy             
# of new VMMC per year 36 37 38 39 39 40 40 41 41 42 42 42 
total # of new HIV cases 3188 6326 9778 13522 17468 21586 25979 30547 35227 40048 44972 50059 
47% efficacy             
# of new VMMC per year 36 37 38 39 39 40 40 41 41 42 42 42 
total # of new HIV cases 3188 6319 9765 13502 17439 21550 25935 30493 35165 39977 44892 49970 
λ1=0.0005 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 181 185 189 193 196 199 202 204 206 207 208 209 
total # of new HIV cases 3188 6344 9816 13580 17546 21685 26099 30687 35386 40225 45167 50270 
17% efficacy             
# of new VMMC per year 181 185 189 193 196 199 202 204 206 207 208 209 
total # of new HIV cases 3188 6338 9803 13561 17519 21651 26057 30635 35325 40157 45089 50183 
27% efficacy             
# of new VMMC per year 181 185 189 193 196 199 202 204 206 207 208 209 
total # of new HIV cases 3188 6332 9790 13541 17492 21616 26013 30584 35265 40088 45011 50096 
37% efficacy             
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# of new VMMC per year 181 185 189 193 196 199 202 204 206 207 208 209 
total # of new HIV cases 3188 6326 9777 13521 17463 21579 25967 30529 35201 40013 44927 50002 
47% efficacy             
# of new VMMC per year 181 185 189 193 196 199 202 204 206 207 208 209 
total # of new HIV cases 3188 6319 9763 13499 17433 21540 25919 30471 35133 39936 44840 49904 
λ1=0.001 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 362 371 378 385 392 397 402 406 410 413 415 417 
total # of new HIV cases 3188 6344 9815 13580 17543 21679 26090 30673 35366 40199 45132 50224 
17% efficacy             
# of new VMMC per year 362 371 378 385 392 397 402 406 410 413 415 417 
total # of new HIV cases 3188 6338 9803 13559 17515 21644 26046 30619 35304 40127 45050 50132 
27% efficacy             
# of new VMMC per year 362 371 378 385 392 397 402 406 410 413 415 417 
total # of new HIV cases 3188 6332 9789 13538 17485 21604 25996 30560 35234 40046 44959 50031 
37% efficacy             
# of new VMMC per year 362.47
6 
371 378 385 392 397 402 406 410 413 415 417 
total # of new HIV cases 3188 6325 9775 13517 17455 21566 25949 30502 35166 39967 44868 49927 
47% efficacy             
# of new VMMC per year 362 371 378 385 392 397 402 406 410 413 415 417 
total # of new HIV cases 3188 6319 9762 13494 17424 21526 25897 30440 35092 39882 44771 49818 
λ1=0.005 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 1812 1847 1878 1905 1929 1950 1968 1982 1994 2002 2007 2009 
total # of new HIV cases 3188 6343 9812 13570 17524 21644 26031 30582 35233 40013 44881 49897 
17% efficacy             
# of new VMMC per year 1812 1847 1878 1905 1929 1950 1968 1982 1994 2002 2007 2009 
total # of new HIV cases 3188 6337 9796 13544 17485 21592 25963 30494 35126 39885 44732 49725 
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27% efficacy             
# of new VMMC per year 1812.3
8 
1847 1878 1905 192 1950 1968 1982 1994 2002 2007 2009 
total # of new HIV cases 3188 6330 9781 13518 17446 21538 25891 30404 35016 39753 44576 49544 
37% efficacy             
# of new VMMC per year 1812.3
8 
1847 1878 1905 1929 1950 1968 1982 1994 2002 2007 2009 
total # of new HIV cases 3188 6323 9765 13490 17403 21479 25814 30308 34897 39612 44411 49353 
47% efficacy             
# of new VMMC per year 1812 1847 1878 1905 1929 1950 1968 1982 1994 2002 2007 2009 
total # of new HIV cases 3188 6316 9747 13461 17360 21420 25737 30209 34776 39466 44239 49154 
λ1=0.01 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 3625 3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 
total # of new HIV cases 3188 6345 9814 13569 17516 21624 25990 30509 35119 39845 44646 49579 
17% efficacy             
# of new VMMC per year 3624.7
6 
3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 
total # of new HIV cases 3188 6335 9791 13527 17449 21530 25862 30344 34913 39595 44350 49234 
27% efficacy             
# of new VMMC per year 3624.7
6 
3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 
total # of new HIV cases 3188 6328 9771 13493 17395 21452 25758 30209 34746 39392 44108 48952 
37% efficacy             
# of new VMMC per year 3624.7
6 
3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 
total # of new HIV cases 3188 6320 9751 13457 17339 21373 25651 30072 34574 39183 43860 48661 
47% efficacy             
# of new VMMC per year 3625 3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 
total # of new HIV cases 3188 6312 9731 13420 17283 21292 25540 29927 34393 38962 43596 48352 
  λ1=0.05 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
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7% efficacy             
# of new VMMC per year 18124 17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 
total # of new HIV cases 3188 6341 9792 13502 17367 21346 25520 29779 34054 38362 42658 46990 
17% efficacy             
# of new VMMC per year 18123.
8 
17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 
total # of new HIV cases 3188 6324 9736 13387 17172 21054 25112 29241 33373 37530 41668 45834 
27% efficacy             
# of new VMMC per year 18123.
8 
17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 
total # of new HIV cases 3188 6310 9692 13295 17017 20820 24785 28808 32826 36860 40868 44900 
37% efficacy             
# of new VMMC per year 18123.
8 
17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 
total # of new HIV cases 3188 6296 9646 13200 16856 20578 24446 28360 32257 36161 40034 43924 
47% efficacy             
# of new VMMC per year 18124 17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 
total # of new HIV cases 3188 6324 9736 13387 17172 21054 25112 29241 33373 37530 41668 45834 
λ1=0.1 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 36248 33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18094 
total # of new HIV cases 3188 6336 9765 13425 17199 21039 25014 29009 32957 36869 40703 44502 
17% efficacy             
# of new VMMC per year 36247.
6 
33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18094 
total # of new HIV cases 3188 6310 9673 13228 16864 20537 24318 28101 31823 35499 39093 42650 
27% efficacy             
# of new VMMC per year 36248 33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18094 
total # of new HIV cases 3188 6289 9599 13070 16596 20135 23760 27371 30910 34396 37795 41153 
37% efficacy             
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# of new VMMC per year 36247.
6 
33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18093 
total # of new HIV cases 3188 6268 9523 12908 16319 19720 23183 26615 29962 33246 36439 39587 
47% efficacy             
# of new VMMC per year 36248 33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18094 
total # of new HIV cases 3188 6246 9444 12739 16032 19288 22582 25825 28971 32043 35018 37943 
λ1=0.15 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy             
# of new VMMC per year 54371 48067 42665 38042 34099 30740 26264 24084 22230 20655 19316 18176 
total # of new HIV cases 3188 6332 9741 13354 17049 20771 24582 28358 32035 35626 39097 42492 
17% efficacy             
# of new VMMC per year 54371 48067 42665 38042 34099 30740 27873 25434 23362 21601 20107 18836 
total # of new HIV cases 3188 6297 9613 13083 16591 20093 23654 27174 30593 33928 37150 40302 
27% efficacy             
# of new VMMC per year 54371 48067 42665 38042 34099 30740 27873 25434 23362 21601 20107 18836 
total # of new HIV cases 3188 6269 9512 12867 16225 19550 22911 26213 29407 32512 35504 38430 
37% efficacy             
# of new VMMC per year 54371 48067 42665 38042 34099 30740 27873 25434 23362 21601 20107 18836 
total # of new HIV cases 3188 6240 9407 12643 15848 18990 22141 25217 28174 31038 33788 36471 
47% efficacy             
# of new VMMC per year 54371 48067 42665 38042 34099 30740 27873 25434 23362 21601 20107 18836 
total # of new HIV cases 3188 6210 9299 12412 15455 18406 21338 24176 26886 29495 31988 34416 
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Appendix 1 
Parameters for the model  
Basic model formula for prediction  
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Appendix 2. Calculation for HIV incidence and prevalence 
 
Based upon the formula:  
 Odds ratio (OR)=odds of HIV infection among circumcised/odds of HIV infection among 
uncircumcised=[prev1/(1-prev1)] /[prev2/(1-prev2)] 
 Prevalence = Incidence*Average Duration of HIV/AIDS  
 Prev1 is the HIV prevalence among circumcised MSM 
 Prev2 is the HIV prevalence among uncircumcised MSM (from the HIV surveillance 
data) 
 OR is calculated from Zhang et al.’s study (Zhang, Qian, et al., Under review)  
 Duration: On average, life expectancy is 14.9 years with ART treatment after the 
incubation time (averagely 8 years), and 1.6 years without ART treatment for a given 
patient.  With 50% ART coverage rate in China,  the average during of HIV/AIDS is 
approximately 16 years from HIV diagnosis to death considering both scenarios of ART 
and non-ART. 
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CHAPTER VI 
MODELING ECONOMIC AND EPIDEMIOLOGICAL IMPACT OF VOLUNTARY 
MEDICAL MALE CIRCUMCISION AMONG MEN WHO HAVE SEX WITH MEN 
IN CHINA: A DECISION ANALYSIS 
 
Abstract 
Introduction: Voluntary medical male circumcision (VMMC) among men who have sex 
with men (MSM) may protect against HIV acquisition. We conducted a series of analyses 
to assess if expanded VMMC might reduce HIV incidence among MSM effectively and 
economically.   
Methods: We used a deterministic compartmental model to project new HIV cases (2016-
2026) under annual VMMC coverage rates (λ) ranging from 0.0001 to 0.15. The “number 
needed to avert (NNA)” that defined as the number of VMMC per new HIV case averted 
was calculated. The breakeven point that balances VMMC cost with saved cost from 
averting HIV cases was also identified. A series sensitivity analyses were conducted with 
different protective efficacies.  
Results: Compared with the baseline circumcision coverage rate, we projected that new 
HIV cases would be reduced with increasing coverage. By 2026 (last year simulated), the 
model generated the lowest ratio (2.29) when the annual circumcision rate was the most 
optimistic (λ=0.15).  The breakeven point was observed at the year of 2019 with the 
annual VMMC coverage rate of 0.001. Sensitivity analyses showed that the higher the 
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protective efficacy of VMMC, a lower coverage rate and less time was required to reach 
the breakeven point.   
Discussion: Our model suggests that acceleration in VMMC implementation among 
MSM could help stem the HIV/AIDS epidemic. The model is dependent upon two 
uncertain understudied parameters, namely the true efficacy of VMMC for HIV 
prevention and the likelihood that health authorities will launch, and MSM will accept, 
VMMC for HIV control in MSM. 
Key words: Male Circumcision; HIV; Men who have Sex with Men; China; “number 
needed to avert” analysis 
Introduction 
     Three randomized controlled trials (RCT) have shown voluntary medical male 
circumcision (VMMC) to be effective in reducing HIV acquisition among heterosexual 
men by over 50% (Auvert et al., 2005; Bailey et al., 2007; R. H. Gray, Kigozi, et al., 
2007). However, the role of VMMC in preventing HIV infection among men who have 
sex with men (MSM) is controversial and circumstantial (Baral, Sifakis, Cleghorn, & 
Beyrer, 2007; Millett et al., 2008; Qian et al., 2015; Smith, Tapsoba, Peshu, Sanders, & 
Jaffe, 2009; Vermund & Qian, 2008). In a meta-analysis using published data through 
August 2016 assessing the efficacy of VMMC among MSM, 30 of 33 studies reported 
non-significant associations between VMMC and HIV although the meta-analysis 
suggested an overall weak, but significant protective efficacy  (Zhang et al., under 
review)(Zhang, Qian, et al., Under review). Two studies from India suggested that 
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VMMC might reduce HIV risk significantly among MSM, even among males who 
primarily practiced receptive sex (Schneider et al., 2012a; Solomon et al., 2014). Among 
MSM in Beijing, a remarkably strong protection effect was noted, especially among 
MSM who predominately practice insertive sex (aOR=0.15, 95% CI=0.04, 0.65) vs. 
MSM who were uncircumcised and practicing receptive and/or versatile (both receptive 
and insertive) sexual positioning. These Asian studies found the strongest evidence to 
date that VMMC might be a useful biomedical tool for HIV risk reduction among MSM, 
especially for MSM with comparatively lower risk profiles, such as MSM practicing 
insertive anal intercourse in Asia (Zhang, Qian, et al., Under review). Circumcision is 
rare in Asia except among Muslims, and circumcised men have undergone the procedure 
in childhood or adolescence, typically, due to pre-existing medical conditions such as 
phimosis (Ben et al., 2009).  Hence, the observational studies comparing circumcised and 
uncircumcised men are not likely to be biased, given the lack of association between 
phimosis and later sexual preference.  
     The willingness of VMMC uptake among Chinese males ranged from less than one-
third among male miners in Guangxi (F. M. Wei et al., 2012), to more than two-thirds 
among general Chinese male population who received an intervention for circumcision 
uptake promotion (Luo et al., 2011; Ruan et al., 2009). The willingness for receiving 
VMMC among MSM was consistent with that among general population in China, 
among whom two-thirds of them expressed their willingness to accept the VMMC as a 
strategy to prevent HIV and other sexually transmitted infections (Lau et al., 2011; Luo et 
al., 2011).Well-designed interventions may facilitate increased willingness of accepting 
VMMC among MSM in China (Lau et al., 2012). For instance, an intervention 
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successfully increased the willingness to be circumcised from 8.1% to 35.1% among a 
group of bisexual MSM in the Southern China (Lau et al., 2012). Therefore, promoting 
VMMC may be beneficial for HIV prevention and is also feasible among MSM, 
particularly among some subgroups including youths and those who practice insertive 
anal sex 
     To assess long-term population-level impacts of expanding VMMC among MSM, 
we should consider the balance between investment (e.g., costs for VMMC performed) 
and impact (e.g., numbers of new HIV cases averted). The United States Agency for 
International Development (USAID) and the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) have developed a modeling tool called “Decision Makers’ 
Program Planning Tool” (DMPPT) to facilitate decision makers’ estimates of the 
epidemiological impact and cost of alternative programmatic options for scaling up 
VMMC (Kripke & Njeuhmeli, 2016; Kripke et al., 2016; Njeuhmeli et al., 2011). 
However, these model-based studies only focused on heterosexual sexual men in specific 
settings (e.g., African nations) with generalized HIV epidemics (Bollinger et al., 2009; 
Kripke & Njeuhmeli, 2016; Njeuhmeli et al., 2011; Stover et al., 2016). 
     The DMPPT model assumes the HIV incidence rate to remain constant during the 
prediction period, resulting in potentially over- or underestimating the impact of VMMC 
(Kripke et al., 2016). To date, no analogous modeling studies have specifically addressed 
the potential utility of circumcision programs targeting MSM. Given the lower 
prevalence of VMMC among Chinese MSM (Beyrer et al., 2012; Vermund & Qian, 
2008; Zhang, Qian, et al., Under review), it is conceivable that VMMC would have a 
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greater impact in China than in areas of high circumcision prevalence (e.g., the United 
States). In order to assess context-specific impacts of VMMC among MSM in China, we 
conducted the current analysis to assess the extent to which expanding VMMC programs 
might reduce HIV incidence among MSM effectively and economically.     
Methods 
Model Building Procedure  
     We employed a deterministic compartmental model to project the HIV epidemic for 
the period between 2016 and 2026 among MSM in Beijing (Zhang, Shephard, et al., 
Under review). Susceptible men are HIV-uninfected, in contrast to HIV-infected men. 
The fixed estimate for the protective efficacy of VMMC is derived from the meta-
analysis (Zhang et al., under review)(Zhang, Qian, et al., Under review) and is set 
conservatively at 7%.  It is plausible that efficacy for HIV prevention in MSM is much 
higher than this (Qian et al., 2016). The study population fell into four mutually exclusive 
subgroups: (1) circumcised susceptible MSM (Sc+); (2) circumcised infected MSM (Ic+); 
(3) uncircumcised susceptible MSM (Sc-); and (4) uncircumcised infected MSM (Ic-). 
With the HIV transmission rate of ρ-, uncircumcised susceptible MSM (Sc-) became 
uncircumcised infected MSM (Ic-). Similarly, with the HIV transmission rate of ρ
+
, 
circumcised susceptible MSM (Sc+) became circumcised infected MSM (Ic+). In this 
dynamic model, seronegative MSM entered the susceptible pool at a rate of σ. The rate of 
entering the circumcised susceptible compartment (Sc+) was σ
+, while σ- represented the 
rate of entering the uncircumcised susceptible compartment (Sc-). Meanwhile, MSM were 
considered to have left the susceptible pool by aging beyond 65 years, emigrating out of 
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Beijing, or dying of any cause. We used the parameter τ to indicate the rate of leaving the 
model among susceptible MSM, with τ+ representing the rate of leaving the circumcised 
susceptible pool (Sc+), and τ
-
 representing the rate of leaving the uncircumcised 
susceptible pool (Sc-). In this model, susceptible MSM would change from being 
uncircumcised to being circumcised at a rate of λ.  
     As very few MSM are expected to be circumcised after HIV infection (Lou et al., 
2014), we did not consider the number of infected MSM who transited from being 
uncircumcised to being circumcised.  Both circumcised and uncircumcised MSM would 
leave the infectious compartments for one reason: 1) death due to HIV infection, or 2) 
having undetectable viral loads due to either being an immunologically elite controller 
(e.g., the small group of HIV-infected patients who can maintain high CD4+ cell counts  
and low viral loads without progressing immunologically towards AIDS over years in 
absence of ART (Pantaleo et al., 1995)) or an effective ART regime at a rate of 𝜂− for 
uncircumcised and  𝜂+ for circumcised MSM (Figure 1). When possible, demographic 
and transmission parameters were estimated from the published literature (Lou et al., 
2014; Lou & Smith, 2011; Lou et al., 2009) or from available unpublished data sources 
(personal communication); a few parameters were calculated within the model itself 
(Supplementary Table 1).  
     In order to refine the model to provide the most valid predictions, we calibrated the 
model parameters to enable the model to predict historical surveillance data. When the 
prediction model overlapped with the surveillance data, using plausible and defensible 
parameter estimations, we considered the generated model to serve well for predictions 
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forward in time. Additionally, through 50 repeated simulations, we generated the 
predicted transmission rates (e.g., ρ- and ρ+) for 2016-2025 among both uncircumcised 
and circumcised MSM 
Economic impact analysis  
     In order to assess the economic impact for VMMC scale-up among MSM, we 
conducted the current analysis from the perspectives of budget holders and health 
professionals (Sullivan et al., 2014). We employed the “numbers needed to avert” 
(NNA) that defined as “the number of VMMC per new HIV case averted” as an 
indicator. NNA was calculated by dividing the number of HIV cases averted (compared 
with the baseline [λ=0.0001]) by the number of VMMC conducted at a given year. The 
lower the NNA, the more economically effective the VMMC campaign would be among 
MSM. We calculated the NNA under different annual VMMC coverage rates at each 
predicted year.  
     In addition, we further identified the breakeven point that balances the total cost of 
VMMC with the cost saved from averting new HIV cases. The breakeven point can be 
considered as the tipping point that it was economically desirable to proceed with the 
VMMC program among MSM in Beijing. We also calculated the total cost saved 
compared to the cost at baseline after expanding the VMMC program in each projected 
year. The cost at each scenario included the cost of VMMC and cost of HIV treatment. 
The cost of each individual VMMC and HIV treatment in each projected year (2016-
2026) was discounted by 3% (Hunink et al., 2001)that started from the baseline cost 
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derived from existing studies (Drabo et al., 2016; Farnham et al., 2013; Moon et al., 
2008; Schackman et al., 2015)(Supplementary Table 2).  
Sensitivity analyses  
     We conducted sensitivity analyses by setting the transmission rates for both 
circumcised and uncircumcised MSM at the same level as the incidence rate seen in 
2015. If nothing changes from 2015 (i.e., very, very few VMMC), it represents a lower 
bound for the transmission rate (Supplementary Figure 1). In addition, we assessed the 
economic impact in terms of the NNA and breakeven points by different protective 
efficacies(e.g., 7%, 17%, 27%, 37%, and 47%)  ranging from being very conservative 7% 
(Zhang, Qian, et al., Under review) to being optimistic 47%(Qian et al., 2016) 
incrementally in the current study.   
Results 
Model predictions of the numbers of new HIV cases and averted HIV cases 
     We presented findings from the prediction model in Table 1, including the number 
of new VMMC, total number of new HIV cases, and numbers of HIV cases averted 
compared to baseline at each predicted year (2016-2026), varying the annual coverage 
rates for VMMC from λ=0.0001 to λ=0.15. With an increased VMMC coverage rate, the 
numbers of VMMC were increased proportionately.  For example in the year 2026, under 
a coverage rate of 0.0001 there would be 42 new VMMC in Beijing, but under an annual 
coverage rate of 0.15 there would be 18,836 new VMMC. The number of susceptible 
MSM will have decreased over time in the latter case, but will have changed little in the 
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former. In the model, when a hypothetical VMMC coverage rate was no greater than 
0.01, the number of new VMMC increased linearly with each year due to a minimal 
change in the susceptible MSM. In contrast, when a hypothetical VMMC coverage rate 
reached 0.05 or more, numbers of new VMMC decreased over time due to the decline in 
susceptible uncircumcised MSM. For instance, under an annual VMMC coverage rate of 
0.1, the number of new VMMC would be 33,652 in 2016, decreasing to 18,094 in 2026. 
As expected given the protective estimates of VMMC for HIV prevention in MSM, new 
HIV cases decreased as VMMC coverage increased. By contracting the number of new 
HIV cases at the baseline from the number of new HIV cases under different hypothetical 
coverage rates of VMMC, we calculated the potential number of HIV cases averted 
(Table 1).  
Economic impact assessment 
     Numbers of VMMC needed per HIV case averted under different coverage rates 
were presented in Table 2. Our analyses revealed that the higher the VMMC coverage 
rate was, the fewer numbers of VMMC was needed for one HIV case averted. For 
instance, under the VMMC coverage rate of 0.0005, the number of VMMC for averting 
one HIV case was 6.74 at 2026, and the number dropped to 5.42 when the coverage rate 
increased to 0.001, 4.97 under the coverage rate of 0.005, 4.79 under the coverage rate of 
0.01, 3.79 under the coverage rate of 0.05, 2.91 under the coverage rate of 0.1, and 2.29 
under the coverage rate of 0.15 (Table 2). We further presented the NNA for the last a 
few years (2021-2026) in Supplementary Figure 2.  
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     We further calculated the prevalence of VMMC over the projected period (2016-
2026). If the annual circumcision coverage rate remained at the 2015 baseline 
(λ=0.0001), the prevalence of VMMC would remain stable over the projected years 
(1.89% in 2015 vs. 1.74% in 2026), while with a high annual coverage rate (λ=0.15) in 
the 2016-2026 period, the coverage would rise from 1.89% in 2015 to 58.8% in 2026 
(Table 3).   
     The analytical result for the “breakeven point” was presented in Table 4. We 
compared the cost spent for expanding VMMC with the cost saved from averting HIV 
cases. At the year of 2019 with the annual VMMC coverage rate of 0.001, the cost after 
scaling up VMMC was approximately equal to the cost at the baseline (costed save was 
approximately equal to zero), which was considered as the breakeven point of the 
VMMC coverage rate. Therefore, it is economically desirable to proceed with the 
VMMC program forward among MSM in Beijing, China beyond the breakeven point in 
terms of the time (e.g.,2019)  and the coverage rate (e.g., 0.001). The amount of cost 
saved got increased with a higher coverage rate. Compared to baseline, the saved cost 
ranged from $2534.2 (in 1000 USD) under the coverage rate of 0.0005 to $811092.2 (in 
1000 USD) under the coverage rate of 0.15. 
Results from sensitivity analyses 
     In the sensitivity analyses, the same pattern for HIV infections and susceptibility by 
circumcision status was observed when the transmission rates were set at the same 
incidence rate seen in 2015.The higher the VMMC coverage rate, the fewer numbers of 
VMMC needed per HIV case averted. Similarly, the trend of a lower NNA was observed 
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for each given coverage rate over time. For the year of 2026, the lowest ratio was 5.23 
when the annual coverage rate of VMMC was 0.15 (Supplementary Table 3).  
     A series of sensitivity analyses with incrementally increased protective efficacies 
revealed that the higher the protective efficacy of VMMC, the lower coverage rate and 
less time was required to reach the breakeven point. For instance, at the protective 
efficacy of 17%,27% and 37%, the breakeven point was achieved in the year of 2018 
with the coverage rate of 0.0005; while the breakeven point was achieved earlier (e.g., 
2017) with the same coverage rate (e.g., λ=0.0005) when the protective efficacy increased 
to 47% (Supplementary Table 4-5). The amount of cost saved increased either with a 
higher protective efficacy for each given coverage rate, or with a higher coverage rate for 
each given protective efficacy (Supplementary Figure 3).  
Discussion 
     We employed a deterministic, compartmental model to assess epidemiologic and 
economic impact of expanding VMMC on HIV prevention among MSM in China. 
Economic impact analysis was an essential part of a comprehensive assessment of a 
health intervention, playing an increasingly important role in decision-making for policy 
makers in the current study(Sullivan et al., 2014). We found that the higher the annual 
coverage rate, the lower numbers of VMMC needed per HIV case averted was over time. 
A lower NNA can be obtained by expanding VMMC campaign significantly among 
MSM, which in turn, requires a higher budget cost of scaling-up the VMMC. If we 
achieved the greatest impact with the NNA as low as 2.29 when the annual VMMC 
coverage rate was 0.15, a total of 330,826 VMMC would be conducted by the year of 
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2026. On the other hand, if we adopted the most frugal budget to provide a low annual 
coverage rate (e.g., 0.0005) of VMMC, the impact would be trivial even though this 
coverage is five times the very low baseline. Furthermore, the analyses for “breakeven 
points” and total cost saved compared to baseline can assist health authorities to visualize 
time period and coverage rate for the tipping point of the intervention. Therefore, 
preventive health and decision-makers can use findings from the current modeling study 
for resource and budget planning.  
     A study conducted among heterosexual men in high HIV prevalence settings 
indicated that one HIV infection can be averted by every five to 15 male circumcisions 
performed over a 10-year time-frame with a 80% VMMC coverage (Group, 2009). Our 
study revealed that to avert one HIV case, 11 to 22 male circumcisions needed to be 
performed on average over a 10-year period with an eventual 58.7% VMMC coverage 
(Table 2). However, at the end of the projection time period (e.g., year of 2026), only two 
to seven VMMC would have to be performed in order to avert one HIV infection among 
MSM, even with our use of very conservative estimates of the efficacy of VMMC in 
protecting MSM (e.g., 7%) (Zhang et al., under review) (Zhang, Qian, et al., Under 
review). With a higher protective efficacy, fewer numbers of VMMC would be needed 
for averting one HIV case (Supplementary Table 4). Although WHO/UNAIDS guidance 
has stated that the VMMC would exert its greatest potential public health impact in 
settings where HIV prevalence exceeds 15% (Group, 2009; WHO/UNAIDS, 2007), the 
HIV prevalence in Chinese MSM approaches this prevalence in many cities(Vermund & 
Qian, 2008; Zeng et al., 2014; Zhang, Qian, et al., Under review; Zhang, Shephard, et al., 
Under review; C. Zhou et al., 2013). Hence, the argument for VMMC deployment among 
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Chinese MSM rivals that for heterosexual men in Africa, even with a lower anticipated 
efficacy (e.g., 7%) (Zhang et al., under review) (Zhang, Qian, et al., Under review), 
though this assumption may overly conservative (Qian et al., 2016).   
     Several strengths of our study are notable, particularly its unique contribution to the 
existing literature. Although the current study employed a deterministic compartmental 
model similar to the DMPPT of UNAIDS/UNAID (Kripke et al., 2016), we simulated 
transmission rates based upon the National HIV Surveillance data in order to capture 
possible randomness properties (Vynnycky & White, 2010). Compared to the arbitrary 
15% variance strategy that employed by other published studies (Kripke & Njeuhmeli, 
2016; Kripke et al., 2016), the HIV surveillance data can improve the validity of the 
model parameters and likely accuracy of context-specific predictions. In addition to the 
simulation, sensitivity analyses estimated new HIV cases at their lower bound when 
transmission rates remained the same as seen in 2015, suggesting our findings to be 
robust and plausible. Both parameter (e.g., uncertainty of transmission rates) and 
structural uncertainties (e.g., uncertainty of VMMC coverage rates) were assessed. The 
analyses based upon incrementally increased protective efficacies also comprehensively 
assessed the intervention impact of VMMC. Furthermore, as one of the first prediction 
models to evaluate VMMC from an economic perspective outside Africa (Goodreau et 
al., 2014), our model assists decision making and resource planning for other settings 
similar to China, especially for places where MSM increasingly dominated the HIV 
epidemic.    
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     Limitations of other models also apply here. Our model in the current study has 
limited generalizability due to the context-specific parameters although we used a meta-
analysis derived circumcision efficacy estimate which would presumably apply to many 
settings(Zhang, Qian, et al., Under review). Unlike the DMPPT model in which age-
specific VMMC scaling up strategies were assessed (Kripke et al., 2016), we only 
assessed the overall epidemic among all MSM with an extended age range from 18 to 65 
years old. In addition, we did not assess epidemiologic and economic impacts of VMMC 
with other concurrent behavioral (e.g., condom use), structural (e.g., microfinance for at-
risk populations) or biomedical intervention strategies (e.g., pre-exposure prophylaxis) 
(Lou et al., 2014; Rotheram-Borus, Swendeman, & Chovnick, 2009; Vermund & Qian, 
2008).  The nature of these available tools depends on user-adherence, a potential 
disadvantage compared to VMMC (Huang et al., 2014; Lou et al., 2014; Pretorius et al., 
2010; Rotheram-Borus et al., 2009; Vermund & Qian, 2008). If acceptable, if offered, 
and if taken up by MSM, VMMC can confer potentially lifelong protective benefits once 
the one-time surgical procedure is performed (Group, 2009). Future research can consider 
synergistic effects of other available prevention tools (Lou et al., 2014) as well as 
considering indirect protective effects toward women and children among bisexual men 
who get circumcised (Group, 2009; Kripke et al., 2016), or potential modulation of 
benefit due to risk compensation after the VMMC procedure was conducted (Group, 
2009). Finally, due to the controversial definition of quality-adjusted life year, we did not 
conduct the cost-effectiveness analysis as other investigators have done (Anderson et al., 
2009; Kahn, Marseille, & Auvert, 2006; Sansom et al., 2010). Nonetheless, these current 
analyses can provide health system and decision-makers estimates useful for deciding 
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when and how to deploy a VMMC scale-up strategy among MSM in settings like China 
(Sullivan et al., 2014).  
     Our model serves as one of the first studies to provide economic data (e.g., 
breakeven analysis, NNA, total cost saved), suggesting VMMC to be a viable prevention 
option for control of HIV among MSM in China and similar venues. Policy-makers 
would do well to consider accelerating access to VMMC targeting MSM, a neglected 
component in the “prevention tool box” to stem the HIV/AIDS epidemic.  
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Table 11. Results from mathematical modeling of predicting HIV cases at different 
voluntary medical male circumcision coverage rates (2016-2026)   
Year 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Total number 
λ1=0.0001 (baseline) 
# of new VMMC 
per year 
37 38 39 39 40 40 41 41 42 42 42 441 
total # of new 
HIV cases 
(baseline)  
6344 9816 13581 17547 21688 26104 30694 35397 40242 45190 50301 296904 
λ1=0.0005 
# of new VMMC 
per year 
185 189 193 196 199 202 204 206 207 208 209 2198 
 # of new HIV 
cases 
6344 9816 13580 17546 21685 26099 30687 35386 40225 45167 50270 296805 
# HIV cases 
averted vs. 
baseline 
0 0 1 1 3 5 7 11 17 23 31 99 
λ1=0.001 
# of new VMMC 
per year 
371 378 386 392 397 402 406 410 413 415 417 4387 
# of new HIV 
cases 
6344 9815 13580 17543 21679 26090 30673 35366 40199 45132 50224 296645 
# HIV cases 
averted vs. 
baseline 
0 0 1 4 9 14 21 31 43 58 77 259 
λ1=0.005 
# of new VMMC 
per year 
1847 1878 1905 1929 1950 1968 1982 1994 2002 2007 2009 21471 
# of new HIV 
cases 
6343 9812 13570 17524 21644 26031 30582 35233 40013 44881 49897 295530 
# HIV cases 
averted vs. 
baseline 
1 4 11 24 44 73 113 164 229 308 404 1374 
λ1=0.01 
# of new VMMC 
per year 
3675 3719 3756 3787 3813 3832 3845 3852 3854 3851 3842 41826 
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# of new HIV 
cases 
6343 9809 13560 17501 21603 25961 30472 35073 39788 44577 49499 294186 
# HIV cases 
averted vs. 
baseline 
1 7 21 46 85 143 222 324 454 612 802 2718 
λ1=0.05 
# of new VMMC 
per year 
17671 17221 16776 16340 15915 15496 15086 14689 14302 13927 13561 170984 
# of new HIV 
cases 
6337 9779 13476 17322 21279 25427 29656 33897 38170 42431 46724 284498 
# HIV cases 
averted vs. 
baseline 
7 37 105 225 409 677 1038 1500 2071 2759 3577 12406 
λ1=0.1 
# of new VMMC 
per year 
33652 31295 29157 27226 25485 23909 22488 21211 20060 19026 18094 271603 
# of new HIV 
cases 
6330 9744 13380 17122 20923 24853 28800 32696 36553 40331 44074 274806 
# HIV cases 
averted vs. 
baseline 
13 72 201 425 765 1251 1894 2701 3689 4858 6227 22098 
λ1=0.15 
# of new VMMC 
per year 
48067 42665 38042 34099 30740 27873 25434 23362 21601 20107 18836 330826 
# of new HIV 
cases 
6324 9711 13292 16943 20614 24368 28094 31726 35279 38716 42081 267148 
# HIV cases 
averted vs. 
baseline 
20 104 290 604 1074 1736 2600 3671 4963 6474 8220 29756 
Notes: ρm [ρ-]: transmission rate among uncircumcised; ρp [ρ+]: transmission rate among circumcised; Scp0: number 
of circumcised susceptible MSM; Scm0: number of uncircumcised susceptible MSM; Ichp0: number of circumcised 
infected MSM; Ichm0: number of uncircumcised infected MSM; 
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Table 12. Numbers of voluntary medical male circumcision needed per HIV case 
averted among men who have sex with men under different coverage rates (2016-
2026) 
Year 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Overall 
λ1=0.0005 n/a n/a 193.00 196.00 66.33 40.40 29.14 18.73 12.18 9.04 6.74 22.20 
λ1=0.001 n/a 378.00 385.00 98.00 44.11 28.71 19.33 13.23 9.60 7.16 5.42 16.94 
λ1=0.005 1847.00 469.50 173.18 80.38 44.32 26.96 17.54 12.16 8.74 6.52 4.97 15.63 
λ1=0.01 3675.00 531.29 178.86 82.33 44.86 26.80 17.32 11.89 8.49 6.29 4.79 15.39 
λ1=0.05 2524.43 465.43 159.77 72.62 38.91 22.89 14.53 9.79 6.91 5.05 3.79 13.78 
λ1=0.1 2588.62 434.65 145.06 64.06 33.31 19.11 11.87 7.85 5.44 3.92 2.91 12.29 
λ1=0.15 2403.35 410.24 131.18 56.46 28.62 16.06 9.78 6.36 4.35 3.11 2.29 11.12 
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Table 13. Prevalence of voluntary medical male circumcision among men who have 
sex with men in China under different coverage rates over the projected period 
(2016-2026) 
Coverage  
rates/Year 
2015 
(%) 
2016 
(%) 
2017 
(%) 
2018 
(%) 
2019 
(%) 
2020 
(%) 
2021 
(%) 
2022 
(%) 
2023 
(%) 
2024 
(%) 
2025 
(%) 
2026 
(%) 
λ1=0.0001 1.89 1.87 1.85 1.83 1.82 1.80 1.79 1.78 1.77 1.76 1.75 1.74 
λ1=0.0005 1.89 1.90 1.92 1.93 1.94 1.95 1.95 1.96 1.97 1.97 1.98 1.98 
λ1=0.001 1.89 1.95 2.00 2.05 2.09 2.13 2.16 2.19 2.21 2.23 2.26 2.27 
λ1=0.005 1.89 2.31 2.69 3.02 3.30 3.56 3.79 3.99 4.17 4.33 4.47 4.60 
λ1=0.01 1.89 2.77 3.54 4.21 4.80 5.32 5.78 6.19 6.56 6.88 7.17 7.43 
λ1=0.05 1.89 6.32 10.06 13.25 15.98 18.33 20.37 22.14 23.68 25.03 26.20 27.23 
λ1=0.1 1.89 10.58 17.61 23.36 28.13 32.10 35.44 38.24 40.61 42.61 44.30 45.72 
λ1=0.15 1.89 14.64 24.52 32.29 38.49 43.49 47.53 50.81 53.47 55.63 57.37 58.76 
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Table 14. Cost saved after expanding the voluntary medical male circumcision compared to the baseline under different 
coverage rates 
&, #
 
 
Notes: & in 1,000 US dollars; # if the cost at any given voluntary medical male circumcision coverage rate is higher than the baseline, the number is positive, which means not 
economically desirable; if the cost is lower than the baseline, the number is negative, which means economically desirable;   *total cost at the baseline when λ1=0.0001 @breakeven 
point for the economically desirable of voluntary medical male circumcision (when λ=0.001 at the year of 2019).  
Year  2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Total cost 
cost at baseline* 150964.0 240589.4 342848.3 456249.4 580836.7 720089.6 872089.2 1035904.8 1213026.9 1403026.6 1608538.4 8624163.3 
cost saved at 
0.0005 
34.2 35.9 12.5 13.6 -39.0 -94.5 -153.9 -275.1 -464.3 -664.1 -939.5 
-2534.2 
cost saved at 
0.001 
77.2 56.4 59.8 -15.0
@
 -148.2 -289.2 -495.9 -802.4 -1187.8 -1688.5 -2346.1 
-6779.8 
cost saved at 
0.005 
394.3 339.9 179.5 -121.7 -681.8 -1497.0 -2646.4 -4244.8 -6330.4 -9002.1 -12309.3 
-35919.9 
cost saved at 0.01 816.6 704.5 380.5 -251.6 -1295.4 -2928.4 -5257.6 -8399.5 -12571.8 -17885.3 -24468.4 -71156.3 
cost saved at 0.05 3906.9 3182.7 1449.9 -1742.4 -6825.9 -14532.8 -25339.2 -39737.5 -58292.4 -81479.3 -110194.4 -329604.4 
cost saved at 0.1 7431.9 5674.5 2059.9 -4199.3 -13871.8 -28111.9 -47617.0 -73032.5 -105352.3 -145143.2 -193530.9 -595692.5 
cost saved at 0.15 10619.0 7571.8 2015.2 -7121.5 -20780.8 -40428.3 -66862.7 -100808.7 -143304.5 -194958.7 -257033.0 -811092.2 
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Figure 17. Transmission rates of HIV among men who have sex with men during 
2016-2025 (remains the same transmission rate as seen in 2015) 
 
 
Figure 18. Numbers of VMMC needed per new HIV case averted at different 
coverage rates among men who have sex with men in China (2021-2026) 
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Figure 19. Saved cost from averting new HIV cases by expanding voluntary medical 
male circumcision among men who have sex with men in China 
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Table 15. Cost of voluntary medical male circumcision and HIV treatment after 
discounting at the rate of 3% (in US dollars) 
Year Cost of HIV treatment 
*
 Cost of male circumcision 
&
 
2016 23794.83 230.77 
2017 24508.67 237.69 
2018 25243.94 244.82 
2019 26001.25 252.17 
2020 26781.29 259.73 
2021 27584.73 267.53 
2022 28412.27 275.55 
2023 29264.64 283.82 
2024 30142.58 292.33 
2025 31046.86 301.10 
2026 31978.26 310.14 
 
Notes:  
*
The cost of HIV treatment for each given HIV infected person is calculated by summing 
costs of HIV testing, hospitalization and ARV medication  
 ART treatment: (500/m*12m)/6.5*24y (average survival time after ARV)1,2 
=923*24=$22153.85 per HIV infected person in lifetime 
 Cost of test before entering free ARV program: $150.75 3 
 Hospitalization: 24.43*61=$ 1490.233 
Total cost for a HIV infected person on average at the year of 2016:  
ARV+ Test+ Hospitalization=$22153.85+$1490.23+$150.75=$23794.83 
&
Circumcision cost at the year of 2016: 1500/6.5= $230.7692 per MSM (1 USD =6.5 RMB at 
the time of the current study) 
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Table 16. Results from sensitivity analyses when remaining the same transmission rates as seen in 2015 (2016-2026)  
Coverage 
rates 
 Items/Years 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
λ1=0.0001 # of new VMMC per year 37 38 39 40 40 41 42 43 44 45 45 
  total # of new HIV cases 6344 9226 11864 14284 16511 18565 20465 22228 23868 25399 26832 
λ1=0.0005 # of new VMMC per year 185 190 194 198 202 206 210 214 218 222 226 
  total # of new HIV cases 6344 9226 11862 14282 16508 18561 20460 22221 23859 25388 26818 
  # of HIV averted  0 0 1 3 3 4 6 7 9 11 14 
  # of VMMC/HIV case averted     145.54 76.65 69.75 48.15 37.43 30.61 23.41 20.39 15.90 
λ1=0.001 # of new VMMC per year 371 379 387 395 403 411 419 427 434 442 449 
  total # of new HIV cases 6344 9225 11862 14280 16505 18555 20452 22210 23845 25371 26797 
  # of HIV averted  0 0 2 4 6 10 14 18 23 28 35 
  # of VMMC/HIV case averted     201.34 90.69 66.69 42.06 30.97 23.33 18.84 15.71 12.88 
λ1=0.005 # of new VMMC per year 1847 1881 1914 1947 1980 2012 2043 2075 2106 2136 2166 
  total # of new HIV cases 8895 11486 13863 16048 18062 19922 21644 23242 24730 26117 27416 
  # of HIV averted  -2551 -2260 -1999 -1764 -1551 -1357 -1179 -1014 -862 -719 -584 
  # of VMMC/HIV case averted -0.72 -0.83 -0.96 -1.10 -1.28 -1.48 -1.73 -2.05 -2.44 -2.97 -3.71 
λ1=0.01 # of new VMMC per year 3675 3725 3774 3823 3870 3917 3963 4009 4053 4097 4141 
  total # of new HIV cases 6343 9220 11847 14251 16454 18477 20338 22053 23637 25103 26462 
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  # of HIV averted  1 6 17 34 57 88 127 175 231 296 370 
  # of VMMC/HIV case averted 2696.56 602.40 219.27 113.94 68.32 44.38 31.10 22.92 17.52 13.84 11.20 
λ1=0.05 # of new VMMC per year 17671 17249 16856 16491 16152 15836 15544 15272 15020 14787 14571 
  total # of new HIV cases 6337 9194 11781 14123 16238 18149 19870 21418 22809 24057 25174 
  # of HIV averted  7 32 83 162 273 417 596 810 1059 1342 1658 
  # of VMMC/HIV case averted 2607.04 534.47 203.59 101.97 59.23 38.00 26.10 18.86 14.18 11.02 8.79 
λ1=0.1 # of new VMMC per year 33652 31345 29296 27475 25859 24425 23152 22023 21023 20137 19353 
  total # of new HIV cases 6330 9163 11706 13979 16002 17795 19377 20765 21977 23029 23938 
  # of HIV averted  13 63 158 305 508 770 1089 1463 1891 2370 2894 
  # of VMMC/HIV case averted 2516.96 498.05 185.75 90.02 50.86 31.71 21.26 15.06 11.12 8.50 6.69 
λ1=0.15 # of new VMMC per year 48067 42733 38222 34408 31184 28461 26160 24219 22581 21200 20038 
  total # of new HIV cases 6324 9135 11638 13852 15797 17495 18968 20236 21319 22234 23003 
  # of HIV averted  20 91 226 433 714 1070 1497 1992 2550 3165 3829 
  # of VMMC/HIV case averted 2433.51 468.97 168.93 79.51 43.68 26.59 17.47 12.16 8.86 6.70 5.23 
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Table 17. Numbers of voluntary medical male circumcision needed per HIV case 
averted among men who have sex with men (2016-2026) with protective efficacies 
ranging from 7% to 47% 
Year 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
7% efficacy           
λ1=0.0005 n/a n/a 193.00 196.00 66.33 40.40 29.14 18.73 12.18 9.04 6.74 
λ1=0.001 n/a 378.00 385.00 98.00 44.11 28.71 19.33 13.23 9.60 7.16 5.42 
λ1=0.005 1847.00 469.50 173.18 80.38 44.32 26.96 17.54 12.16 8.74 6.52 4.97 
λ1=0.01 3675.00 531.29 178.86 82.33 44.86 26.80 17.32 11.89 8.49 6.29 4.79 
λ1=0.05 2524.43 465.43 159.77 72.62 38.91 22.89 14.53 9.79 6.91 5.05 3.79 
λ1=0.1 2588.62 434.65 145.06 64.06 33.31 19.11 11.87 7.85 5.44 3.92 2.91 
λ1=0.15 2403.35 410.24 131.18 56.46 28.62 16.06 9.78 6.36 4.35 3.11 2.29 
17% efficacy                       
λ1=0.0005 n/a n/a 96.50 65.33 39.80 25.25 17.00 11.44 8.63 6.50 5.10 
λ1=0.001   378.00 128.33 56.00 33.08 21.16 14.50 10.25 7.51 5.76 4.48 
λ1=0.005 1847.00 268.29 105.83 52.14 30.47 19.29 12.95 9.19 6.76 5.16 4.02 
λ1=0.01 1225.00 286.08 107.31 51.88 30.26 18.97 12.65 8.96 6.58 4.99 3.88 
λ1=0.05 1262.21 257.03 95.86 46.69 26.44 16.26 10.72 7.45 5.39 4.03 3.09 
λ1=0.1 1201.86 238.89 87.30 41.38 22.77 13.69 8.83 6.03 4.28 3.16 2.39 
λ1=0.15 1172.37 224.55 79.25 36.59 19.67 11.57 7.32 4.92 3.45 2.52 1.90 
27% efficacy                       
λ1=0.0005 n/a 189.00 193.00 65.33 33.17 20.20 13.60 9.81 7.14 5.62 4.35 
λ1=0.001 n/a 189.00 77.00 39.20 23.35 14.89 10.41 7.74 5.90 4.66 3.69 
λ1=0.005 923.50 187.80 79.38 39.37 23.21 14.91 10.16 7.36 5.52 4.25 3.35 
λ1=0.01 918.75 185.95 75.12 37.87 22.43 14.46 9.86 7.12 5.32 4.10 3.22 
λ1=0.05 803.23 173.95 67.92 34.11 19.84 12.52 8.42 5.97 4.39 3.33 2.59 
λ1=0.1 782.60 162.99 61.77 30.28 17.14 10.57 6.97 4.85 3.51 2.62 2.01 
λ1=0.15 762.97 152.92 56.28 26.85 14.84 8.96 5.80 3.97 2.84 2.11 1.61 
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37% efficacy                       
λ1=0.0005 n/a 189.00 96.50 39.20 24.88 16.83 11.33 7.92 5.91 4.62 3.67 
λ1=0.001 371.00 126.00 64.17 30.15 19.85 12.97 9.02 6.72 5.10 3.99 3.16 
λ1=0.005 615.67 144.46 57.73 29.68 18.22 11.93 8.29 6.06 4.59 3.58 2.85 
λ1=0.01 612.50 137.74 56.91 29.59 17.90 11.68 8.09 5.90 4.46 3.46 2.75 
λ1=0.05 609.34 130.46 52.10 26.70 15.77 10.11 6.90 4.95 3.68 2.82 2.21 
λ1=0.1 580.21 122.73 47.49 23.70 13.65 8.55 5.72 4.03 2.95 2.23 1.73 
λ1=0.15 558.92 115.00 43.28 21.05 11.84 7.26 4.77 3.31 2.40 1.80 1.39 
47% efficacy                       
λ1=0.0005 n/a 94.50 64.33 32.67 19.90 12.63 9.27 6.44 5.05 4.00 3.17 
λ1=0.001 371.00 126.00 55.00 26.13 16.54 10.58 7.52 5.62 4.30 3.40 2.73 
λ1=0.005 461.75 104.33 46.46 24.42 15.00 9.94 6.95 5.13 3.91 3.07 2.46 
λ1=0.01 459.38 109.38 45.80 24.28 14.72 9.70 6.79 4.99 3.79 2.97 2.37 
λ1=0.05 1262.21 257.03 95.86 46.69 26.44 16.26 10.72 7.45 5.39 4.03 3.09 
λ1=0.1 454.76 97.19 38.21 19.35 11.27 7.13 4.82 3.42 2.53 1.93 1.50 
λ1=0.15 440.98 91.56 34.90 17.19 9.78 6.06 4.03 2.82 2.06 1.56 1.21 
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Table 18. Cost saved after expanding the voluntary medical male circumcision compared to the baseline 
&, #
 
Year  2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Total cost  
7%  efficacy             
Cost at baseline 150964.0 240589.4 342848.3 456249.4 580836.7 720089.6 872089.2 1035904.8 1213026.9 1403026.6 1608538.4 8624163.3 
Cost saved at 0.0005 34.2 35.9 12.5 13.6 -39.0 -94.5 -153.9 -275.1 -464.3 -664.1 -939.5 -2534.2 
Cost saved at 0.001 77.2 56.4 59.8 -15.0
@ -148.2 -289.2 -495.9 -802.4 -1187.8 -1688.5 -2346.1 -6779.8 
Cost saved at 0.005 394.3 339.9 179.5 -121.7 -681.8 -1497.0 -2646.4 -4244.8 -6330.4 -9002.1 -12309.3 -35919.9 
Cost saved at 0.01 816.6 704.5 380.5 -251.6 -1295.4 -2928.4 -5257.6 -8399.5 -12571.8 -17885.3 -24468.4 -71156.3 
Cost saved at 0.05 3906.9 3182.7 1449.9 -1742.4 -6825.9 -14532.8 -25339.2 -39737.5 -58292.4 -81479.3 -110194.4 -329604.4 
Cost saved at 0.1 7431.9 5674.5 2059.9 -4199.3 -13871.8 -28111.9 -47617.0 -73032.5 -105352.3 -145143.2 -193530.9 -595692.5 
Cost saved at 0.15 10619.0 7571.8 2015.2 -7121.5 -20780.8 -40428.3 -66862.7 -100808.7 -143304.5 -194958.7 -257033.0 -811092.2 
17% efficacy                        
Cost at baseline 150822.8 240284.0 342379.6 455604.3 579979.5 719006.5 870774.2 1034342.3 1211192.3 1400888.7 1606092.6 8611366.8 
Cost saved at 0.0005 31.6 25.2 -11.0
@ -50.4 -99.1 -181.6 -302.7 -486.1 -688.4 -939.8 -1266.7 -3969.1 
Cost saved at 0.001 71.2 56.2 7.3 -103.2 -228.4 -429.1 -703.4 -1063.0 -1534.6 -2110.7 -2850.9 -8888.6 
Cost saved at 0.005 384.8 258.2 -0.1 -493.3 -1219.0 -2301.4 -3819.5 -5806.9 -8353.2 -11501.0 -15379.7 -48231.2 
Cost saved at 0.01 773.1 558.4 17.1 -946.3 -2401.2 -4567.8 -7573.7 -11510.6 -16555.7 -22806.9 -30502.4 -95516.0 
Cost saved at 0.05 3738.4 2439.2 -325.5 -4990.1 -11993.1 -22139.2 -35825.0 -53507.2 -75757.4 -103045.8 -136202.1 -437608.0 
Cost saved at 0.1 7104.9 4228.8 -1305.2 -10260.3 -23354.4 -41782.0 -66158.2 -97010.5 -135291.3 -181441.4 -236631.5 -781901.2 
Cost saved at 0.15 10120.2 5483.8 -2797.5 -15640.6 -33887.1 -59029.1 -91682.3 -132397.6 -182193.0 -241456.0 -311482.6 -1054962.0 
131 
 
 27% efficacy                        
Cost at baseline 150680.0 239977.0 341878.1 454900.3 579062.3 717859.5 869388.0 1032679.9 1209237.1 1398626.2 1603503.6 8597792081 
Cost saved at 0.0005 30.3 20.2 2.5
@ -41.2 -119.2 -233.2 -387.5 -579.6 -818.6 5299.5 -1476.0 -4710.5 
Cost saved at 0.001 67.9 22.7 -36.7 -182.7 -370.2 -638.6 -1009.5 -1445.3 -1997.5 -2658.3 -3489.0 -11737.2 
Cost saved at 0.005 30.3 20.2 2.5 -41.2 -119.2 -233.2 -387.5 -579.6 -818.6 -1108.1 -1476.0 -60663.1 
Cost saved at 0.01 737.0 389.5 -351.4 -1650.8 -3564.7 -6306.4 -10018.0 -14756.8 -20733.4 -28048.2 -36932.1 -121235.3 
Cost saved at 0.05 3558.8 1653.6 -2142.2 -8335.2 -17350.5 -30010.8 -46721.7 -67846.9 -94002.3 -125597.4 -163480.2 -550274.8 
Cost saved at 0.1 6751.3 2724.7 -4783.4 -16514.7 -33194.4 -56023.5 -85513.3 -122064.1 -166592.9 -219493.5 -281900.7 -976604.6 
Cost saved at 0.15 9598.3 3303.8 -7750.5 -24434.5 -47500.3 -78387.4 -117600.1 -165452.2 -222917.3 -290272.0 -368766.0 -1310178.2 
 37% efficacy                        
Cost at baseline 150532.3 239664.7 341369.9 454188.2 578110.7 716650.3 867910.8 1030922.0 1207181.6 1396258.5 1600803.6 8583592.628 
Cost saved at 0.0005 28.7 15.0 -7.3
@ -79.9 -164.2 -285.8 -474.0 -701.8 -1006.1 -1336.6 -1777.1 -5789.0 
Cost saved at 0.001 64.5 11.2 -58.5 -240.0 -441.3 -750.7 -1165.3 -1673.4 -2330.3 -3129.4 -4107.5 -13820.9 
Cost saved at 0.005 348.3 110.5 -371.2 -1203.3 -2367.8 -4030.1 -6263.2 -9084.4 -12572.0 -16823.2 -21962.8 -74219.3 
Cost saved at 0.01 699.6 217.1 -750.3 -2391.3 -4721.7 -8045.4 -12447.7 -18020.5 -24965.2 -33383.2 -43527.9 -147336.3 
Cost saved at 0.05 3373.0 850.4 -4039.8 -11806.9 -22885.0 -38151.3 -57995.1 -82739.3 -112989.9 -149120.7 -192007.4 -667512.1 
Cost saved at 0.1 6385.5 1186.7 -8373.6 -23013.4 -43372.7 -70735.6 -105530.0 -148060.3 -199193.2 -259216.2 -329275.2 -1179197.8 
Cost saved at 0.15 9058.4 1052.6 -12887.9 -33534.9 -61550.6 -98430.2 -144436.2 -199773.9 -265310.7 -341205.8 -428682.2 -1575701.5 
 47% efficacy                        
Cost at baseline 150379.3 239345.6 340853.1 453441.9 577146.8 715426.2 866389.8 1029116.7 1205047.4 1393778.6 1597955.9 8568881.3 
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Notes: & in 1,000 US dollars; # if the cost at any given voluntary medical male circumcision coverage rate is higher than the baseline, the number is positive, which means not 
economically desirable; if the cost is lower than the baseline, the number is negative, which means economically desirable;   *total cost at the baseline when λ1=0.0001; 
@breakeven point for the economically desirable coverage rate of voluntary medical male circumcision  
Cost saved at 0.0005 27.2 -12.6
@ -40.4 -118.9 -234.1 -389.5 -587.2 -878.6 -1195.6 -1567.3 -2051.8 -7048.7 
Cost saved at 0.001 60.9 -1.2 -104.4 -298.6 -562.5 -940.1 -1426.5 -2037.5 -2776.4 -3662.1 -4761.2 -16509.5 
Cost saved at 0.005 329.1 0.0 -586.5 -1580.7 -2993.5 -4952.8 -7550.7 -10837.0 -14847.0 -19677.2 -25491.8 -88188.1 
Cost saved at 0.01 661.0 39.7 -1158.3 -3122.3 -5947.4 -9887.3 -15042.7 -21515.4 -29499.4 -39097.0 -50555.2 -175124.3 
Cost saved at 0.05 4181.9 3377.5 1200.9 -2827.7 -9160.4 -18558.8 -31440.7 -48281.6 -69612.5 -95935.8 -128065.4 -395122.5 
Cost saved at 0.1 6006.8 -441.2 -12116.5 -29732.8 -53966.9 -86103.5 -126454.6 -175256.3 -233306.2 -300840.5 -378996.0 -1391207.6 
Cost saved at 0.15 8499.5 -1288.2 -18213.1 -42998.7 -76224.0 -119355.7 -172474.8 -235661.1 -309684.1 -394582.6 -491562.0 -1853544.9 
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CHAPTER VII 
 
SYNOPSIS 
 
        In this dissertation, I conducted a systematic review and meta-analysis to evaluate 
the protective efficacy of the association between male circumcision and HIV infection 
among MSM with a series of sensitivity analyses, employed a transmission model to 
assess the epidemiological impact of VMMC by projecting the HIV incidence for the 
next decade among MSM in Beijing; and determined the budget-impact of VMMC 
program by a decision-modeling strategy.  
     Our meta-analytic review included 117,293 participants from 33 studies, which had 
45,600 more participants and 12 new studies compared with the one conducted by 
Wiysonge and colleagues in 2011 (Wiysonge et al., 2011). Our review showed that the 
odds of being HIV-infected were significantly lower among MSM who were circumcised 
than among MSM who were uncircumcised, but the effect size was modest (7% 
protection, 95% CI, 1%-12%). Our meta-analysis is the first to report a statistically 
protective effect of VMMC against HIV infection among MSM. The evidence for the 
protective effect of VMMC was dramatically stronger among MSM who live in Asia or 
Africa. Our findings suggest that VMMC may be a protective tool against HIV infection 
among MSM, especially for these who living in Asia and Africa (WHO, 2016; Beyrer et 
al., 2016).    
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     Our model predicts the magnitude of the impact of VMMC on HIV acquisition over 
a 11-year period by estimating the reduction in proportion of HIV-infected cases [45]. By 
changing the coverage rates of VMMC from the very low baseline coverage (λ=0.0001) 
to a hypothetical scenario of an active VMMC program (λ=0.15), our model suggested a 
worthwhile potential public health impact of VMMC for MSM in China, depending on 
coverage assumptions, given an assumed efficacy of 7%. This low efficacy was derived 
from a systematic review and meta-analysis, but a 47% (95% confidence interval: -2 to 
+73%) protective efficacy estimate from a Chinese study conducted in 2010-2011 
suggested VMMC to be more beneficial than earlier studies suggested; our estimates of 
benefit are therefore very conservative [33,34]. The reduction in the proportion of HIV-
infected cases ranged from 0.06% when the VMMC coverage rate was low at 0.0001 
(corresponding to the prevalence of VMMC as 1.7%) to 16.3% when the VMMC 
coverage rate increased to 0.15 (corresponding to the VMMC prevalence of 58.8%) by 
the year of 2026. Meanwhile, we observed a big jump of the reduction in the proportion 
of the number of HIV cases (from 0.92% to 4.18%) when the VMMC coverage rate 
increased from 0.01 to 0.05. The big jump may indicate that a slight increase of the 
VMMC coverage rate may result in a significant reduction in new HIV cases among 
MSM in China, even with our use of very conservative estimates of the efficacy of 
VMMC in protecting MSM.   
     Economic impact analysis was an essential part of a comprehensive assessment of a 
health intervention, playing an increasingly important role in decision-making for policy 
makers in the current study (Sullivan et al., 2014). We found that the higher the annual 
coverage rate, the lower numbers of VMMC needed per HIV case averted was over time. 
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A lower NNA can be obtained by expanding VMMC campaign significantly among 
MSM, which in turn, requires a higher budget cost of scaling-up the VMMC. If we 
achieved the greatest impact with the NNA as low as 2.29 when the annual VMMC 
coverage rate was 0.15, a total of 330,826 VMMC would be conducted by the year of 
2026. On the other hand, if we adopted the most frugal budget to provide a low annual 
coverage rate (e.g., 0.0005) of VMMC, the impact would be trivial even though this 
coverage is five times the very low baseline. Furthermore, the analyses for “breakeven 
points” and total cost saved compared to baseline can assist health authorities to visualize 
time period and coverage rate for the tipping point of the intervention. Therefore, 
preventive health and decision-makers can use findings from the current modeling study 
for resource and budget planning.  
     In conclusion, although the overall effect of VMMC on HIV prevention was 
marginally significant, misclassification of key exposure and confounding variables may 
dilute the protective effect of VMMC. In turn, publication bias may exaggerate its 
protective effort. Research with more rigorous study designs to objectively assess HIV 
infection through confirmatory serological tests and evaluation of circumcision by genital 
exam can significantly reduce misclassification bias. In addition, future research should 
collect detailed data on MSM’s sexual position preference at different time points in their 
lives (e.g., in the past 30 days, in the past six months and lifetime), as well as the degree 
of their sexual risk taking. We would not be surprised if we eventually learn that 
circumcision is highly protective for MSM, but benefits are predominantly accrued 
among men practicing predominantly insertive anal sex and men without highest risk 
behavior patterns. Subtypes may also alter the relative benefits seen, but no data exist on 
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this point. Our transmission model serves as one of the first studies to provide economic 
data (e.g., breakeven analysis, NNA, total cost saved), suggesting VMMC to be a viable 
prevention option for control of HIV among MSM in China and similar venues. Policy-
makers would do well to consider accelerating access to VMMC targeting MSM, a 
neglected component in the “prevention tool box” to stem the HIV/AIDS epidemic. A 
randomized clinical trial, if feasible, should be conducted. 
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